Continuous Manufacturing Market

Table of Contents

SECTION I: REPORT OVERVIEW

1. PREFACE
1.1. Introduction
1.2. Market Share Insights
1.3. Key Market Insights
1.4. Report Coverage
1.5. Key Questions Answered
1.6. Chapter Outlines

2. RESEARCH METHODOLOGY
2.1. Chapter Overview
2.2. Research Assumptions
2.2.1. Market Landscape and Market Trends
2.2.2. Market Forecast and Opportunity Analysis
2.2.3. Comparative Analysis

2.3. Database Building
2.3.1. Data Collection
2.3.2. Data Validation
2.3.3. Data Analysis

2.4. Project Methodology
2.4.1. Secondary Research
2.4.1.1. Annual Reports
2.4.1.2. Academic Research Papers
2.4.1.3. Company Websites
2.4.1.4. Investor Presentations
2.4.1.5. Regulatory Filings
2.4.1.6. White Papers
2.4.1.7. Industry Publications
2.4.1.8. Conferences and Seminars
2.4.1.9. Government Portals
2.4.1.10. Media and Press Releases
2.4.1.11. Newsletters
2.4.1.12. Industry Databases
2.4.1.13. Roots Proprietary Databases
2.4.1.14. Paid Databases and Sources
2.4.1.15. Social Media Portals
2.4.1.16. Other Secondary Sources

2.4.2. Primary Research
2.4.2.1. Types of Primary Research
2.4.2.1.1. Qualitative Research
2.4.2.1.2. Quantitative Research
2.4.2.1.3. Hybrid Approach

2.4.2.2. Advantages of Primary Research

2.4.2.3. Techniques for Primary Research
2.4.2.3.1. Interviews
2.4.2.3.2. Surveys
2.4.2.3.3. Focus Groups
2.4.2.3.4. Observational Research
2.4.2.3.5. Social Media Interactions

2.4.2.4. Key Opinion Leaders Considered in Primary Research
2.4.2.4.1. Company Executives (CXOs)
2.4.2.4.2. Board of Directors
2.4.2.4.3. Company Presidents and Vice Presidents
2.4.2.4.4. Research and Development Heads
2.4.2.4.5. Technical Experts
2.4.2.4.6. Subject Matter Experts
2.4.2.4.7. Scientists
2.4.2.4.8. Doctors and Other Healthcare Providers

2.4.2.5. Ethics and Integrity
2.4.2.5.1. Research Ethics
2.4.2.5.2. Data Integrity

2.4.3. Analytical Tools and Databases

2.5. Robust Quality Control

3. MARKET DYNAMICS
3.1. Chapter Overview
3.2. Forecast Methodology
3.2.1. Top-down Approach
3.2.2. Bottom-up Approach
3.2.3. Hybrid Approach

3.3. Market Assessment Framework
3.3.1. Total Addressable Market (TAM)
3.3.2. Serviceable Addressable Market (SAM)
3.3.3. Serviceable Obtainable Market (SOM)
3.3.4. Currently Acquired Market (CAM)

3.4. Forecasting Tools and Techniques
3.4.1. Qualitative Forecasting
3.4.2. Correlation
3.4.3. Regression
3.4.4. Extrapolation
3.4.5. Convergence
3.4.6. Sensitivity Analysis
3.4.7. Scenario Planning
3.4.8. Data Visualization
3.4.9. Time Series Analysis
3.4.10. Forecast Error Analysis

3.5. Key Considerations
3.5.1. Demographics
3.5.2. Government Regulations
3.5.3. Reimbursement Scenarios
3.5.4. Market Access
3.5.5. Supply Chain
3.5.6. Industry Consolidation
3.5.7. Pandemic / Unforeseen Disruptions Impact

3.6. Limitations

4. MACRO-ECONOMIC INDICATORS
4.1. Chapter Overview
4.2. Market Dynamics
4.2.1. Time Period
4.2.1.1. Historical Trends
4.2.1.2. Current and Forecasted Estimates

4.2.2. Currency Coverage
4.2.2.1. Major Currencies Affecting the Market
4.2.2.2. Factors Affecting Currency Fluctuations
4.2.2.3. Impact of Currency Fluctuations on the Industry

4.2.3. Foreign Currency Exchange Rate
4.2.3.1. Impact of Foreign Exchange Rate Volatility on the Market
4.2.3.2. Strategies for Mitigating Foreign Exchange Risk

4.2.4. Recession
4.2.4.1. Assessment of Current Economic Conditions and Potential Impact on the Market
4.2.4.2. Historical Analysis of Past Recessions and Lessons Learnt

4.2.5. Inflation
4.2.5.1. Measurement and Analysis of Inflationary Pressures in the Economy
4.2.5.2. Potential Impact of Inflation on the Market Evolution

4.2.6. Interest Rates
4.2.6.1. Interest Rates and Their Impact on the Market
4.2.6.2. Strategies for Managing Interest Rate Risk

4.2.7. Commodity Flow Analysis
4.2.7.1. Type of Commodity
4.2.7.2. Origins and Destinations
4.2.7.3. Values and Weights
4.2.7.4. Modes of Transportation

4.2.8. Global Trade Dynamics
4.2.8.1. Import Scenario
4.2.8.2. Export Scenario
4.2.8.3. Trade Policies
4.2.8.4. Strategies for Mitigating the Risks Associated with Trade Barriers
4.2.8.5. Impact of Trade Barriers on the Market

4.2.9. War Impact Analysis
4.2.9.1. Russian-Ukraine War
4.2.9.2. Israel-Hamas War

4.2.10. COVID Impact / Related Factors
4.2.10.1. Global Economic Impact
4.2.10.2. Industry-specific Impact
4.2.10.3. Government Response and Stimulus Measures
4.2.10.4. Future Outlook and Adaptation Strategies

4.2.11. Other Indicators
4.2.11.1. Fiscal Policy
4.2.11.2. Consumer Spending
4.2.11.3. Gross Domestic Product (GDP)
4.2.11.4. Employment
4.2.11.5. Taxes
4.2.11.6. Stock Market Performance
4.2.11.7. Cross-Border Dynamics

4.3. Conclusion

SECTION II: QUALITATIVE INSIGHTS

5. EXECUTIVE SUMMARY

6. INTRODUCTION
6.1. Chapter Overview
6.2. Historical Evolution of Continuous Manufacturing

6.3. Continuous Manufacturing in the Pharmaceutical Industry
6.3.1. Regulatory Landscape
6.3.2. Early Adopters of Continuous Manufacturing
6.3.3. Anticipated Shift to Continuous Manufacturing
6.3.4. Batch Manufacturing versus Continuous Manufacturing
6.3.5. Key Challenges Associated with Continuous Manufacturing
6.3.6. Future Perspectives

SECTION III: MARKET OVERVIEW

7. MARKET LANDSCAPE: BIOLOGICS CONTINUOUS MANUFACTURERS
7.1. Chapter Overview
7.2. Biologics Continuous Manufacturers: Overall Market Landscape
7.2.1. Analysis by Year of Establishment
7.2.2. Analysis by Company Size
7.2.3. Analysis by Location of Headquarters
7.2.4. Analysis by Type of Player
7.2.5. Analysis by Scale of Operation
7.2.6. Analysis by Type of Biologic Manufactured
7.2.7. Analysis by Type of Product Manufactured
7.2.8. Analysis by Location of Continuous Manufacturing Facilities
7.2.9. Analysis by Type of Continuous Manufacturing Facility
7.2.10. Analysis by Stage of Bioprocessing
7.2.11. Analysis by Stage of Upstream Bioprocessing
7.2.12. Analysis by Stage of Downstream Bioprocessing
7.2.13. Analysis by Quality Certificates Obtained
7.2.14. Analysis by Range of Installed Capacity

8. COMPANY COMPETITIVENESS ANALYSIS: CONTINUOUS BIOLOGIC MANUFACTURERS
8.1. Chapter Overview
8.2. Assumptions and Key Parameters
8.3. Methodology

8.4. Company Competitiveness Analysis: Continuous Biologics Manufacturers
8.4.1. Biologics Continuous Manufacturers based in North America
8.4.2. Biologics Continuous Manufacturers based in Europe
8.4.3. Biologics Continuous Manufacturers based in Asia-Pacific

9. MARKET LANDSCAPE: SMALL MOLECULES CONTINUOUS MANUFACTURERS
9.1. Chapter Overview
9.2. Small Molecule Continuous Manufacturers: Overall Market Landscape
9.2.1. Analysis by Year of Establishment
9.2.2. Analysis by Company Size
9.2.3. Analysis by Location of Headquarters
9.2.4. Analysis by Type of Player
9.2.5. Analysis by Scale of Operation
9.2.6. Analysis by Type of Dosage Form
9.2.7. Analysis by Type of Product Manufactured
9.2.8. Analysis by Location of Continuous Manufacturing Facilities
9.2.9. Analysis by Type of Continuous Manufacturing Process
9.2.10. Analysis by Stage of API Manufacturing
9.2.11. Analysis by Stage of FDF Manufacturing
9.2.12. Analysis by Quality Certificates Obtained

10. COMPANY COMPETITIVENESS ANALYSIS: CONTINUOUS SMALL MOLECULE MANUFACTURERS
10.1. Chapter Overview
10.2. Assumptions and Key Parameters
10.3. Methodology

10.4. Company Competitiveness Analysis: Continuous Small Molecule Manufacturers
10.4.1. Small Molecules Continuous Manufacturers based in North America
10.4.2. Small Molecules Continuous Manufacturers based in Europe
10.4.3. Small Molecules Continuous Manufacturers based in Asia-Pacific

SECTION IV: COMPANY PROFILES

11. COMPANY PROFILES: CONTINUOUS MANUFACTURING SERVICE PROVIDERS BASED IN NORTH AMERICA
11.1. Chapter Overview
11.2. AbbVie Contract Manufacturing
11.2.1. Company Overview
11.2.2. Financial Information
11.2.3. Continuous Manufacturing Service Portfolio
11.2.4. Continuous Manufacturing Facilities
11.2.5. Recent Developments and Future Outlook

11.3. Abzena
11.3.1. Company Overview
11.3.2. Continuous Manufacturing Service Portfolio
11.3.3. Continuous Manufacturing Facilities
11.3.4. Recent Developments and Future Outlook

11.4. AGC Biologics
11.4.1. Company Overview
11.4.2. Financial Information
11.4.3. Continuous Manufacturing Service Portfolio
11.4.4. Continuous Manufacturing Facilities
11.4.5. Recent Developments and Future Outlook

11.5. Phlow
11.5.1. Company Overview
11.5.2. Continuous Manufacturing Service Portfolio
11.5.3. Continuous Manufacturing Facilities
11.5.4. Recent Developments and Future Outlook

12. COMPANY PROFILES: CONTINUOUS MANUFACTURING SERVICE PROVIDERS BASED IN EUROPE
12.1. Chapter Overview
12.2. Boehringer Ingelheim
12.2.1. Company Overview
12.2.2. Financial Information
12.2.3. Continuous Manufacturing Service Portfolio
12.2.4. Continuous Manufacturing Facilities
12.2.5. Recent Developments and Future Outlook

12.3. Corden Pharma
12.3.1. Company Overview
12.3.2. Continuous Manufacturing Service Portfolio
12.3.3. Continuous Manufacturing Facilities
12.3.4. Recent Developments and Future Outlook

12.4. Glatt
12.4.1. Company Overview
12.4.2. Continuous Manufacturing Service Portfolio
12.4.3. Continuous Manufacturing Facilities
12.4.4. Recent Developments and Future Outlook

13. COMPANY PROFILES: CONTINUOUS MANUFACTURING SERVICE PROVIDERS BASED IN ASIA-PACIFIC
13.1. Chapter Overview
13.2. Kaneka
13.2.1. Company Overview
13.2.2. Financial Information
13.2.3. Continuous Manufacturing Service Portfolio
13.2.4. Continuous Manufacturing Facilities
13.2.5. Recent Developments and Future Outlook

13.3. WuXi Biologics
13.3.1. Company Overview
13.3.2. Financial Information
13.3.3. Continuous Manufacturing Service Portfolio
13.3.4. Continuous Manufacturing Facilities
13.3.5. Recent Developments and Future Outlook

SECTION V: MARKET TRENDS

14. PARTNERSHIPS AND COLLABORATIONS
14.1. Chapter Overview
14.2. Partnership Models

14.3. Continuous Manufacturing: Partnerships and Collaborations
14.3.1. Analysis by Year of Partnership
14.3.2. Analysis by Type of Partnership
14.3.3. Analysis by Year and Type of Partnership
14.3.4. Analysis by Type of Partner
14.3.5. Analysis by Type of Drug Molecule
14.3.6. Analysis by Type of Product
14.3.7. Analysis by Scale of Operation
14.3.8. Most Active Players: Analysis by Number of Partnerships

14.3.9. Analysis by Geography
14.3.9.1. Analysis by Country
14.3.9.2. Analysis by Continent

15. RECENT EXPANSIONS
15.1. Chapter Overview
15.2. Continuous Manufacturing: Recent Expansions
15.2.1. Analysis by Year of Expansion
15.2.2. Analysis by Type of Expansion
15.2.3. Analysis by Year and Type of Expansion
15.2.4. Analysis by Scale of Operation
15.2.5. Analysis by Type of Expansion and Scale of Operation
15.2.6. Analysis by Type of Drug Molecule
15.2.7. Analysis by Type of Expansion and Type of Drug Molecule
15.2.8. Analysis by Type of Product
15.2.9. Analysis by Amount Invested
15.2.10. Analysis by Facility Area
15.2.11. Most Active Players: Analysis by Number of Recent Expansions

15.2.12. Analysis by Location of Expansion
15.2.12.1. Analysis by Country
15.2.12.2. Analysis by Continent

15.2.13. Analysis by Location of Expansion (Continent) and Type of Expansion

16. GRANT ANALYSIS
16.1. Chapter Overview
16.2. Scope and Methodology

16.3. Continuous Manufacturing: Grants Analysis
16.3.1. Analysis by Year of Grants Award
16.3.2. Analysis by Amount Awarded
16.3.3. Analysis by Funding Institute Center
16.3.4. Analysis by Support Period
16.3.5. Analysis by Type of Grant Application
16.3.6. Analysis by Purpose of Grant Award
16.3.7. Analysis by Activity Code
16.3.8. Analysis by Study Section Involved
16.3.9. Popular NIH Departments: Analysis by Number of Grants
16.3.10. Analysis by Type of Recipient Organization
16.3.11. Prominent Program Officers: Analysis by Number of Grants
16.3.12. Popular Recipient Organizations: Analysis by Number of Grants
16.3.13. Popular Recipient Organizations: Analysis by Grant Amount
16.3.14. Analysis by Region of Recipient Organization

17. PATENT ANALYSIS
17.1. Chapter Overview
17.2. Scope and Methodology

17.3. Continuous Manufacturing: Patent Analysis
17.3.1. Analysis by Patent Publication Year
17.3.2. Analysis by Type of Patent and Publication Year
17.3.3. Analysis by Patent Application Year
17.3.4. Analysis by Patent Jurisdiction
17.3.5. Analysis by CPC Symbols
17.3.6. Analysis by Type of Applicant
17.3.7. Leading Industry Players: Analysis by Number of Patents
17.3.8. Leading Non-Industry Players: Analysis by Number of Patents

17.4. Patent Benchmarking Analysis
17.4.1. Analysis by Patent Characteristics

17.5. Patent Valuation
17.6. Leading Patents by Number of Citations

18. GAPS ASSOCIATED WITH CONTINUOUS BIOPROCESSING
18.1. Chapter Overview

18.2. Technological Gaps in Continuous Bioprocessing
18.2.1. Gaps related to Bioburden Control
18.2.2. Gaps related to Continuous Multi Column Chromatography
18.2.2.1. Continuous Chromatography Systems
18.2.2.2. Continuous Protein A Chromatography
18.2.2.3. Continuous Anion Exchange Chromatography
18.2.2.4. Continuous Flow-Through Processing
18.2.2.5. Continuous Chromatography Media

18.2.3. Gaps related to Continuous Viral Inactivation
18.2.3.1. Continuous Viral Inactivation in a Tubular Reactor
18.2.3.2. Continuous Viral Inactivation Through Column Chromatography
18.2.3.3. Continuous Viral Inactivation using Alternating Hold-Bags

18.2.4. Gaps related to Continuous Viral Filtration
18.2.5. Gaps related to Continuous Ultrafiltration / Diafiltration
18.2.6. Gaps related to Continuous Buffer Supply
18.2.7. Gaps related to Continuous On-line Monitoring

18.3. Other Gaps Associated with Continuous Bioprocessing
18.3.1. Gaps Related to Single-Use Technologies
18.3.2. Gaps Related to Process Automation
18.3.3. Regulatory Requirements

18.4. Concluding Remarks

19. INITIATIVES OF COMPANIES WITH IN-HOUSE CONTINUOUS CAPABILITIES
19.1. Chapter Overview
19.2. Continuous Manufacturing Initiatives undertaken by Leading Companies
19.2.1. Amgen
19.2.1.1. In-House Initiatives

19.2.2. Boehringer Ingelheim
19.2.2.1. In-House Initiatives

19.2.3. Bristol-Myers Squibb
19.2.3.1. In-House Initiatives
19.2.3.2. Partnered Initiatives

19.2.4. GSK
19.2.4.1. In-House Initiatives
19.2.4.2. Partnered Initiatives

19.2.5. Merck KGaA
19.2.5.1. In-House Initiatives
19.2.5.2. Partnered Initiatives

19.2.6. Novartis
19.2.6.1. In-House Initiatives
19.2.6.2. Partnered Initiatives

19.2.7. Pfizer
19.2.7.1. In-House Initiatives
19.2.7.2. Partnered Initiatives

19.2.8. Sanofi
19.2.8.1. In-House Initiatives
19.2.8.2. Partnered Initiatives

20. CASE STUDY 1: CONTINUOUS MANUFACTURING EQUIPMENT FOR BIOLOGICS
20.1. Chapter Overview
20.2. Biologics Continuous Manufacturing Equipment: Overall Market Landscape
20.2.1. Analysis by Type of Equipment
20.2.2. Analysis by Type of Manufacturing Process
20.2.3. Analysis by Stage of Bioprocessing
20.2.4. Analysis by Scale of Operation

20.3. Biologics Continuous Manufacturing Equipment: Developer Landscape
20.3.1. Analysis by Year of Establishment
20.3.2. Analysis by Company Size
20.3.3. Analysis by Location of Headquarters
20.3.4. Most Active Players: Analysis by Number of Biologics Continuous Manufacturing Equipment Offered

21. CASE STUDY 2: ROADMAP FOR THE ADOPTION OF CONTINUOUS MANUFACTURING PROCESSES
21.1. Chapter Overview
21.2. Challenges Associated with the Adoption of Continuous Manufacturing Processes
21.3. Key Strategies for the Adoption of Continuous Manufacturing Processes
21.3.1. Phase I: Process Development and Implementation
21.3.2. Phase II: Equipment / Technology Development and Installation
21.3.3. Phase III: Facility / Plant Development and Establishment
21.3.4. Phase IV: Product Development and Manufacturing

22. CASE STUDY 3: MODULAR FACILITIES IN PHARMACEUTICAL / BIOTECHNOLOGY INDUSTRY
22.1. Chapter Overview
22.2. Historical Background

22.3. The Concept of Modularization
22.3.1. Types of Modular Constructs
22.3.2. Modular Construction Process

22.4. Modular Construction in the Pharmaceutical Industry
22.4.1. Advantages of Modular Construction in the Pharmaceutical Industry

22.5. Modular Facility Manufacturers
22.5.1. Analysis by Type of Industry Served
22.5.2. Analysis by Geographical Coverage
22.5.3. Analysis by Type of Modular Construction

22.6. Modular Pharmaceutical Cleanrooms
22.6.1. Cleanroom Classifications and Current Standards
22.6.2. Regulations and Standards Concerning Modular Cleanroom Construction
22.6.3. Advantages of Modular Cleanrooms

22.7. Modular Cleanroom Providers
22.7.1. Analysis by Year of Establishment
22.7.2. Analysis by Location of Headquarters
22.7.3. Analysis by Type of Modular Cleanroom Offered

22.8. Conclusion

23. CAPACITY ANALYSIS: CONTINUOUS BIOLOGIC MANUFACTURERS
23.1. Chapter Overview
23.2. Key Assumptions and Methodology
23.2.1. Analysis by Range of Installed Capacity
23.2.2. Analysis by Company Size
23.2.3. Analysis by Scale of Operation
23.2.4. Analysis by Type of Player

23.2.5. Analysis by Location of Biologics Continuous Manufacturing Facility
23.2.5.1. Analysis of Biologics Continuous Manufacturing Capacity Installed in North America
23.2.5.2. Analysis of Biologics Continuous Manufacturing Capacity Installed in Europe
23.2.5.3. Analysis of Biologics Continuous Manufacturing Capacity Installed in Asia-Pacific

23.2.6. Concluding Remarks

24. CAPACITY ANALYSIS: CONTINUOUS SMALL MOLECULES MANUFACTURERS
24.1. Chapter Overview
24.2. Key Assumptions and Methodology
24.2.1. Analysis by Range of Installed Capacity
24.2.2. Analysis by Company Size
24.2.3. Analysis by Scale of Operation
24.2.4. Analysis by Type of Player

24.2.5. Analysis by Location of Small Molecules Continuous Manufacturing Facility
24.2.5.1. Analysis of Small Molecules Continuous Manufacturing Capacity Installed in North America
24.2.5.2. Analysis of Small Molecules Continuous Manufacturing Capacity Installed in Europe
24.2.5.3. Analysis of Small Molecules Continuous Manufacturing Capacity Installed in Asia-Pacific

24.2.6. Concluding Remarks

SECTION VI: MARKET FORECAST AND OPPORTUNITY ANALYSIS

25. GLOBAL CONTINUOUS MANUFACTURING MARKET
25.1. Chapter Overview
25.2. Assumptions and Methodology

25.3. Global Continuous Manufacturing Market, Historical Trends (Since 2021) and Forecasted Estimates (Till 2035)
25.3.1. Scenario Analysis
25.3.1.1. Conservative Scenario
25.3.1.2. Optimistic Scenario

25.4. Key Market Segmentations

26. CONTINUOUS MANUFACTURING MARKET, BY TYPE OF DRUG MOLECULE
26.1. Chapter Overview
26.2. Key Assumptions and Methodology

26.3. Continuous Manufacturing Market: Distribution by Type of Drug Molecule
26.3.1. Continuous Manufacturing Market for Biologics, Historical Trends (Since 2021) and Forecasted Estimates (Till 2035)
26.3.1.1. Biologics Continuous Manufacturing Market for Upstream Bioprocessing, Historical Trends (Since 2021) and Forecasted Estimates (Till 2035)
26.3.1.2. Biologics Continuous Manufacturing Market for Downstream Bioprocessing, Historical Trends (Since 2021) and Forecasted Estimates (Till 2035)

26.3.2. Continuous Manufacturing Market for Small Molecules, Historical Trends (Since 2021) and Forecasted Estimates (Till 2035)
26.3.2.1. Small Molecules Continuous Manufacturing Market for Active Pharmaceutical Ingredients, Historical Trends (Since 2021) and Forecasted Estimates (Till 2035)
26.3.2.2. Small Molecules Continuous Manufacturing Market for Finished Dosage Forms, Historical Trends (Since 2021) and Forecasted Estimates (Till 2035)

26.4. Data Triangulation and Validation

27. CONTINUOUS MANUFACTURING MARKET, BY SCALE OF OPERATION
27.1. Chapter Overview
27.2. Key Assumptions and Methodology

27.3. Biologics Continuous Manufacturing Market: Distribution by Scale of Operation
27.3.1. Biologics Continuous Manufacturing Market for Preclinical / Clinical Scale Operations, Historical Trends (Since 2021) and Forecasted Estimates (Till 2035)
27.3.2. Biologics Continuous Manufacturing Market for Commercial Scale Operations, Historical Trends (Since 2021) and Forecasted Estimates (Till 2035)

27.4. Small Molecules Continuous Manufacturing Market: Distribution by Scale of Operation
27.4.1. Small Molecules Continuous Manufacturing Market for Preclinical / Clinical Scale Operations, Historical Trends (Since 2021) and Forecasted Estimates (Till 2035)
27.4.2. Small Molecules Continuous Manufacturing Market for Commercial Scale Operations, Historical Trends (Since 2021) and Forecasted Estimates (Till 2035)

27.5. Data Triangulation and Validation

28. CONTINUOUS MANUFACTURING MARKET, BY PURPOSE OF MANUFACTURING
28.1. Chapter Overview
28.2. Key Assumptions and Methodology

28.3. Biologics Continuous Manufacturing Market: Distribution by Purpose of Manufacturing
28.3.1. Biologics Continuous Manufacturing Market for Contract Manufacturing, Historical Trends (Since 2021) and Forecasted Estimates (Till 2035)
28.3.2. Biologics Continuous Manufacturing Market for In-house Manufacturing, Historical Trends (Since 2021) and Forecasted Estimates (Till 2035)
28.3.3. Biologics Continuous Manufacturing Market for Both, Historical Trends (Since 2021) and Forecasted Estimates (Till 2035)

28.4. Small Molecules Continuous Manufacturing Market: Distribution by Purpose of Manufacturing
28.4.1. Small Molecules Continuous Manufacturing Market for Contract Manufacturing, Historical Trends (Since 2021) and Forecasted Estimates (Till 2035)
28.4.2. Small Molecules Continuous Manufacturing Market In-house Manufacturing, Historical Trends (Since 2021) and Forecasted Estimates (Till 2035)
28.4.3. Small Molecules Continuous Manufacturing Market for Both, Historical Trends (Since 2021) and Forecasted Estimates (Till 2035)

28.5. Data Triangulation and Validation

29. CONTINUOUS MANUFACTURING MARKET, BY COMPANY SIZE
29.1. Chapter Overview
29.2. Key Assumptions and Methodology

29.3. Biologics Continuous Manufacturing Market: Distribution by Company Size
29.3.1. Biologics Continuous Manufacturing Market for Small Companies, Historical Trends (Since 2021) and Forecasted Estimates (Till 2035)
29.3.2. Biologics Continuous Manufacturing Market for Mid-sized Companies, Historical Trends (Since 2021) and Forecasted Estimates (Till 2035)
29.3.3. Biologics Continuous Manufacturing Market for Large Companies, Historical Trends (Since 2021) and Forecasted Estimates (Till 2035)

29.4. Small Molecules Continuous Manufacturing Market: Distribution by Company Size
29.4.1. Small Molecules Continuous Manufacturing Market for Small Companies, Historical Trends (Since 2021) and Forecasted Estimates (Till 2035)
29.4.2. Small Molecules Continuous Manufacturing Market for Mid-sized Companies, Historical Trends (Since 2021) and Forecasted Estimates (Till 2035)
29.4.3. Small Molecules Continuous Manufacturing Market for Large Companies, Historical Trends (Since 2021) and Forecasted Estimates (Till 2035)

29.5. Data Triangulation and Validation

30. CONTINUOUS MANUFACTURING MARKET, BY KEY GEOGRAPHICAL REGIONS
30.1. Chapter Overview
30.2. Key Assumptions and Methodology

30.3. Biologics Continuous Manufacturing Market: Distribution by Key Geographical Regions
30.3.1. Biologics Continuous Manufacturing Market in North America, Historical Trends (Since 2021) and Forecasted Estimates (Till 2035)
30.3.1.1. Biologics Continuous Manufacturing Market in the US, Historical Trends (Since 2021) and Forecasted Estimates (Till 2035)
30.3.1.2. Biologics Continuous Manufacturing Market in Puerto Rico, Historical Trends (Since 2021) and Forecasted Estimates (Till 2035)

30.3.2. Biologics Continuous Manufacturing Market in Europe, Historical Trends (Since 2021) and Forecasted Estimates (Till 2035)
30.3.2.1. Biologics Continuous Manufacturing Market in Germany, Historical Trends (Since 2021) and Forecasted Estimates (Till 2035)
30.3.2.2. Biologics Continuous Manufacturing Market in Switzerland, Historical Trends (Since 2021) and Forecasted Estimates (Till 2035)
30.3.2.3. Biologics Continuous Manufacturing Market in Belgium, Historical Trends (Since 2021) and Forecasted Estimates (Till 2035)
30.3.2.4. Biologics Continuous Manufacturing Market in Ireland, Historical Trends (Since 2021) and Forecasted Estimates (Till 2035)
30.3.2.5. Biologics Continuous Manufacturing Market in France, Historical Trends (Since 2021) and Forecasted Estimates (Till 2035)
30.3.2.6. Biologics Continuous Manufacturing Market in Rest of Europe, Historical Trends (Since 2021) and Forecasted Estimates (Till 2035)

30.3.3. Biologics Continuous Manufacturing Market in Aisa-Pacific, Historical Trends (Since 2021) and Forecasted Estimates (Till 2035)
30.3.3.1. Biologics Continuous Manufacturing Market in China, Historical Trends (Since 2021) and Forecasted Estimates (Till 2035)
30.3.3.2. Biologics Continuous Manufacturing Market in South Korea, Historical Trends (Since 2021) and Forecasted Estimates (Till 2035)
30.3.3.3. Biologics Continuous Manufacturing Market in Singapore, Historical Trends (Since 2021) and Forecasted Estimates (Till 2035)
30.3.3.4. Biologics Continuous Manufacturing Market in Taiwan, Historical Trends (Since 2021) and Forecasted Estimates (Till 2035)
30.3.3.5. Biologics Continuous Manufacturing Market in India, Historical Trends (Since 2021) and Forecasted Estimates (Till 2035)
30.3.3.6. Biologics Continuous Manufacturing Market in Japan, Historical Trends (Since 2021) and Forecasted Estimates (Till 2035)
30.3.3.7. Biologics Continuous Manufacturing Market in Australia, Historical Trends (Since 2021) and Forecasted Estimates (Till 2035)

30.4. Small Molecules Continuous Manufacturing Market: Distribution by Key Geographical Regions, 2018, Current Year and 2040
30.4.1. Small Molecules Continuous Manufacturing Market in North America, Historical Trends (Since 2021) and Forecasted Estimates (Till 2035)
30.4.1.1. Small Molecules Continuous Manufacturing Market in the US, Historical Trends (Since 2021) and Forecasted Estimates (Till 2035)
30.4.1.2. Small Molecules Continuous Manufacturing Market in Mexico, Historical Trends (Since 2021) and Forecasted Estimates (Till 2035)

30.4.2. Small Molecules Continuous Manufacturing Market in Europe, Historical Trends (Since 2021) and Forecasted Estimates (Till 2035)
30.4.2.1. Biologics Continuous Manufacturing Market in Germany, Historical Trends (Since 2021) and Forecasted Estimates (Till 2035)
30.4.2.2. Small Molecules Continuous Manufacturing Market in the UK, Historical Trends (Since 2021) and Forecasted Estimates (Till 2035)
30.4.2.3. Small Molecules Continuous Manufacturing Market in Italy, Historical Trends (Since 2021) and Forecasted Estimates (Till 2035)
30.4.2.4. Small Molecules Continuous Manufacturing Market in Switzerland, Historical Trends (Since 2021) and Forecasted Estimates (Till 2035)
30.4.2.5. Small Molecules Continuous Manufacturing Market in France, Historical Trends (Since 2021) and Forecasted Estimates (Till 2035)
30.4.2.6. Small Molecules Continuous Manufacturing Market in Belgium, Historical Trends (Since 2021) and Forecasted Estimates (Till 2035)
30.4.2.7. Small Molecules Continuous Manufacturing Market in Rest of Europe, Historical Trends (Since 2021) and Forecasted Estimates (Till 2035)

30.4.3. Small Molecules Continuous Manufacturing Market in Aisa-Pacific, Historical Trends (Since 2021) and Forecasted Estimates (Till 2035)
30.4.3.1. Small Molecules Continuous Manufacturing Market in China, Historical Trends (Since 2021) and Forecasted Estimates (Till 2035)
30.4.3.2. Small Molecules Continuous Manufacturing Market in Japan, Historical Trends (Since 2021) and Forecasted Estimates (Till 2035)
30.4.3.3. Small Molecules Continuous Manufacturing Market in Singapore, Historical Trends (Since 2021) and Forecasted Estimates (Till 2035)
30.4.3.4. Small Molecules Continuous Manufacturing Market in South Korea, Historical Trends (Since 2021) and Forecasted Estimates (Till 2035)
30.4.3.5. Small Molecules Continuous Manufacturing Market in India, Historical Trends (Since 2021) and Forecasted Estimates (Till 2035)

30.5. Data Triangulation and Validation

SECTION VII: MARKET OPPORTUNITY ANALYSIS WITHIN GEOGRAPHICAL REGIONS

31. MARKET OPPORTUNITY ANALYSIS: NORTH AMERICA
31.1. Continuous Manufacturing Market in North America: Distribution by Type of Drug Molecule
31.1.1. Continuous Manufacturing Market in North America for Biologics, Historical Trends (Since 2021) and Forecasted Estimates (Till 2035)
31.1.1.1. Biologics Continuous Manufacturing Market in North America for Upstream Bioprocessing, Historical Trends (Since 2021) and Forecasted Estimates (Till 2035)
31.1.1.2. Biologics Continuous Manufacturing Market in North America for Downstream Bioprocessing, Historical Trends (Since 2021) and Forecasted Estimates (Till 2035)

31.1.2. Continuous Manufacturing Market in North America for Small Molecules, Historical Trends (Since 2021) and Forecasted Estimates (Till 2035)
31.1.2.1. Small Molecules Continuous Manufacturing Market in North America for Active Pharmaceutical Ingredients, Historical Trends (Since 2021) and Forecasted Estimates (Till 2035)
31.1.2.2. Small Molecules Continuous Manufacturing Market in North America for Finished Dosage Forms, Historical Trends (Since 2021) and Forecasted Estimates (Till 2035)

31.2. Continuous Manufacturing Market in North America: Distribution by Scale of Operation
31.2.1. Biologics Continuous Manufacturing Market in North America for Preclinical / Clinical Scale Operations, Historical Trends (Since 2021) and Forecasted Estimates (Till 2035)
31.2.2. Biologics Continuous Manufacturing Market in North America for Commercial Scale Operations, Historical Trends (Since 2021) and Forecasted Estimates (Till 2035)
31.2.3. Small Molecules Continuous Manufacturing Market in North America for Preclinical / Clinical Scale Operations, Historical Trends (Since 2021) and Forecasted Estimates (Till 2035)
31.2.4. Small Molecules Continuous Manufacturing Market in North America for Commercial Scale Operations, Historical Trends (Since 2021) and Forecasted Estimates (Till 2035)

31.3. Continuous Manufacturing Market in North America: Distribution by Purpose of Manufacturing
31.3.1. Biologics Continuous Manufacturing Market in North America for Contract Manufacturing, Historical Trends (Since 2021) and Forecasted Estimates (Till 2035)
31.3.2. Biologics Continuous Manufacturing Market in North America for In-House Manufacturing, Historical Trends (Since 2021) and Forecasted Estimates (Till 2035)
31.3.3. Biologics Continuous Manufacturing Market in North America for Both, Historical Trends (Since 2021) and Forecasted Estimates (Till 2035)
31.3.4. Small Molecules Continuous Manufacturing Market in North America for Contract Manufacturing, Historical Trends (Since 2021) and Forecasted Estimates (Till 2035)
31.3.5. Small Molecules Continuous Manufacturing Market in North America for In-House Manufacturing, Historical Trends (Since 2021) and Forecasted Estimates (Till 2035)
31.3.6. Small Molecules Continuous Manufacturing Market in North America for Both, Historical Trends (Since 2021) and Forecasted Estimates (Till 2035)

31.4. Continuous Manufacturing Market in North America: Distribution by Company Size
31.4.1. Biologics Continuous Manufacturing Market in North America for Small Companies, Historical Trends (Since 2021) and Forecasted Estimates (Till 2035)
31.4.2. Biologics Manufacturing Market in North America for Mid-sized Companies, Historical Trends (Since 2021) and Forecasted Estimates (Till 2035)
31.4.3. Biologics Manufacturing Market in North America for Large Companies, Historical Trends (Since 2021) and Forecasted Estimates (Till 2035)
31.4.4. Small Molecules Continuous Manufacturing Market in North America for Small Companies, Historical Trends (Since 2021) and Forecasted Estimates (Till 2035)
31.4.5. Small Molecules Manufacturing Market in North America for Mid-sized Companies, Historical Trends (Since 2021) and Forecasted Estimates (Till 2035)
31.4.6. Small Molecules Manufacturing Market in North America for Large Companies, Historical Trends (Since 2021) and Forecasted Estimates (Till 2035)

32. MARKET OPPORTUNITY ANALYSIS: EUROPE
32.1. Continuous Manufacturing Market in Europe: Distribution by Type of Drug Molecule
32.1.1. Continuous Manufacturing Market in Europe for Biologics, Historical Trends (Since 2021) and Forecasted Estimates (Till 2035)
32.1.1.1. Biologics Continuous Manufacturing Market in Europe for Upstream Bioprocessing, Historical Trends (Since 2021) and Forecasted Estimates (Till 2035)
32.1.1.2. Biologics Continuous Manufacturing Market in Europe for Downstream Bioprocessing, Historical Trends (Since 2021) and Forecasted Estimates (Till 2035)

32.1.2. Continuous Manufacturing Market in Europe for Small Molecules, Historical Trends (Since 2021) and Forecasted Estimates (Till 2035)
32.1.2.1. Small Molecules Continuous Manufacturing Market in Europe for Active Pharmaceutical Ingredients, Historical Trends (Since 2021) and Forecasted Estimates (Till 2035)
32.1.2.2. Small Molecules Continuous Manufacturing Market in Europe for Finished Dosage Forms, Historical Trends (Since 2021) and Forecasted Estimates (Till 2035)

32.2. Continuous Manufacturing Market in Europe: Distribution by Scale of Operation
32.2.1. Biologics Continuous Manufacturing Market in Europe for Preclinical / Clinical Scale Operations, Historical Trends (Since 2021) and Forecasted Estimates (Till 2035)
32.2.2. Biologics Continuous Manufacturing Market in Europe for Commercial Scale Operations, Historical Trends (Since 2021) and Forecasted Estimates (Till 2035)
32.2.3. Small Molecules Continuous Manufacturing Market in Europe for Preclinical / Clinical Scale Operations, Historical Trends (Since 2021) and Forecasted Estimates (Till 2035)
32.2.4. Small Molecules Continuous Manufacturing Market in Europe for Commercial Scale Operations, Historical Trends (Since 2021) and Forecasted Estimates (Till 2035)

32.3. Continuous Manufacturing Market in Europe: Distribution by Purpose of Manufacturing
32.3.1. Biologics Continuous Manufacturing Market in Europe for Contract Manufacturing, Historical Trends (Since 2021) and Forecasted Estimates (Till 2035)
32.3.2. Biologics Continuous Manufacturing Market in Europe for In-House Manufacturing, Historical Trends (Since 2021) and Forecasted Estimates (Till 2035)
32.3.3. Biologics Continuous Manufacturing Market in Europe for Both, Historical Trends (Since 2021) and Forecasted Estimates (Till 2035)
32.3.4. Small Molecules Continuous Manufacturing Market in Europe for Contract Manufacturing, Historical Trends (Since 2021) and Forecasted Estimates (Till 2035)
32.3.5. Small Molecules Continuous Manufacturing Market in Europe for In-House Manufacturing, Historical Trends (Since 2021) and Forecasted Estimates (Till 2035)
32.3.6. Small Molecules Continuous Manufacturing Market in Europe for Both, Historical Trends (Since 2021) and Forecasted Estimates (Till 2035)

32.4. Continuous Manufacturing Market in Europe: Distribution by Company Size
32.4.1. Biologics Continuous Manufacturing Market in Europe for Small Companies, Historical Trends (Since 2021) and Forecasted Estimates (Till 2035)
32.4.2. Biologics Manufacturing Market in Europe for Mid-sized Companies, Historical Trends (Since 2021) and Forecasted Estimates (Till 2035)
32.4.3. Biologics Manufacturing Market in Europe for Large Companies, Historical Trends (Since 2021) and Forecasted Estimates (Till 2035)
32.4.4. Small Molecules Continuous Manufacturing Market in Europe for Small Companies, Historical Trends (Since 2021) and Forecasted Estimates (Till 2035)
32.4.5. Small Molecules Manufacturing Market in Europe for Mid-sized Companies, Historical Trends (Since 2021) and Forecasted Estimates (Till 2035)
32.4.6. Small Molecules Manufacturing Market in Europe for Large Companies, Historical Trends (Since 2021) and Forecasted Estimates (Till 2035)

33. MARKET OPPORTUNITY ANALYSIS: ASIA-PACIFIC
33.1. Continuous Manufacturing Market in Asia-Pacific: Distribution by Type of Drug Molecule
33.1.1. Continuous Manufacturing Market in Asia-Pacific for Biologics, Historical Trends (Since 2021) and Forecasted Estimates (Till 2035)
33.1.1.1. Biologics Continuous Manufacturing Market in Asia-Pacific for Upstream Bioprocessing, Historical Trends (Since 2021) and Forecasted Estimates (Till 2035)
33.1.1.2. Biologics Continuous Manufacturing Market in Asia-Pacific for Downstream Bioprocessing, Historical Trends (Since 2021) and Forecasted Estimates (Till 2035)

33.1.2. Continuous Manufacturing Market in Asia-Pacific for Small Molecules, Historical Trends (Since 2021) and Forecasted Estimates (Till 2035)
33.1.2.1. Small Molecules Continuous Manufacturing Market in Asia-Pacific for Active Pharmaceutical Ingredients, Historical Trends (Since 2021) and Forecasted Estimates (Till 2035)
33.1.2.2. Small Molecules Continuous Manufacturing Market in Asia-Pacific for Finished Dosage Forms, Historical Trends (Since 2021) and Forecasted Estimates (Till 2035)

33.2. Continuous Manufacturing Market in Asia-Pacific: Distribution by Scale of Operation
33.2.1. Biologics Continuous Manufacturing Market in Asia-Pacific for Preclinical / Clinical Scale Operations, Historical Trends (Since 2021) and Forecasted Estimates (Till 2035)
33.2.2. Biologics Continuous Manufacturing Market in Asia-Pacific for Commercial Scale Operations, Historical Trends (Since 2021) and Forecasted Estimates (Till 2035)
33.2.3. Small Molecules Continuous Manufacturing Market in Asia-Pacific for Preclinical / Clinical Scale Operations, Historical Trends (Since 2021) and Forecasted Estimates (Till 2035)
33.2.4. Small Molecules Continuous Manufacturing Market in Asia-Pacific for Commercial Scale Operations, Historical Trends (Since 2021) and Forecasted Estimates (Till 2035)

33.3. Continuous Manufacturing Market in Asia-Pacific: Distribution by Purpose of Manufacturing
33.3.1. Biologics Continuous Manufacturing Market in Asia-Pacific for Contract Manufacturing Historical Trends (Since 2021) and Forecaste Estimates (Till 2035)
33.3.2. Biologics Continuous Manufacturing Market in Asia-Pacific for In-House Manufacturing, Historical Trends (Since 2021) and Forecasted Estimates (Till 2035)
33.3.3. Biologics Continuous Manufacturing Market in Asia-Pacific for Both, Historical Trends (Since 2021) and Forecasted Estimates (Till 2035)
33.3.4. Small Molecules Continuous Manufacturing Market in Asia-Pacific for Contract Manufacturing, Historical Trends (Since 2021) and Forecasted Estimates (Till 2035)
33.3.5. Small Molecules Continuous Manufacturing Market in Asia-Pacific for In-House Manufacturing, Historical Trends (Since 2021) and Forecasted Estimates (Till 2035)
33.3.6. Small Molecules Continuous Manufacturing Market in Asia-Pacific for Both, Historical Trends (Since 2021) and Forecasted Estimates (Till 2035)

33.4. Continuous Manufacturing Market in Asia-Pacific: Distribution by Company Size
33.4.1. Biologics Continuous Manufacturing Market in Asia-Pacific for Small Companies, Historical Trends (Since 2021) and Forecasted Estimates (Till 2035)
33.4.2. Biologics Manufacturing Market in Asia-Pacific for Mid-sized Companies, Historical Trends (Since 2021) and Forecasted Estimates (Till 2035)
33.4.3. Biologics Manufacturing Market in Asia-Pacific for Large Companies, Historical Trends (Since 2021) and Forecasted Estimates (Till 2035)
33.4.4. Small Molecules Continuous Manufacturing Market in Asia-Pacific for Small Companies, Historical Trends (Since 2021) and Forecasted Estimates (Till 2035)
33.4.5. Small Molecules Manufacturing Market in Asia-Pacific for Mid-sized Companies, Historical Trends (Since 2021) and Forecasted Estimates (Till 2035)
33.4.6. Small Molecules Manufacturing Market in Asia-Pacific for Large Companies, Historical Trends (Since 2021) and Forecasted Estimates (Till 2035)

**Detailed information on Section VII is available in the Excel Data Packs shared along with the report**

SECTION VIII: OTHER EXCLUSIVE INSIGHTS

34. CONCLUDING REMARKS

35. EXECUTIVE INSIGHTS
35.1. Chapter Overview
35.2. Company A
35.2.1. Company Snapshot
35.2.2. Interview Transcript (Founder and Chief Executive Officer)

35.3. Company B
35.3.1. Company Snapshot
35.3.2. Interview Transcript (Co-Founder and Chief Business Officer)

35.4. Company C
35.4.1. Company Snapshot
35.4.2. Interview Transcript (Chief Executive Officer)

35.5. Company D
35.5.1. Company Snapshot
35.5.2. Interview Transcript (Chief Scientific Officer)

35.6. Company E
35.6.1. Company Snapshot
35.6.2. Interview Transcript (Senior Director Chemical Research and Development)

35.7. Company F
35.7.1. Company Snapshot
35.7.2. Interview Transcript (Technical Project Manager, Continuous Manufacturing and Crystallization)

SECTION IX: APPENDICES

36. APPENDIX 1: TABULATED DATA

37. APPENDIX 2: LIST OF COMPANIES AND ORGANIZATION

List of Figures

Figure 2.1 Research Methodology: Project Methodology
Figure 2.2 Research Methodology: Data Sources for Secondary Research
Figure 2.3 Research Methodology: Robust Quality Control
Figure 3.1 Market Dynamics: Forecast Methodology
Figure 3.2 Market Dynamics: Market Assessment Framework
Figure 4.1 Lessons Learnt from Past Recessions
Figure 5.1 Executive Summary: Market Landscape
Figure 5.2 Executive Summary: Recent Trends
Figure 5.3 Executive Summary: Market Sizing and Opportunity Analysis
Figure 6.1 Advantages of Continuous Manufacturing
Figure 7.1 Biologics Continuous Manufacturers: Distribution by Year of Establishment
Figure 7.2 Biologics Continuous Manufacturers: Distribution by Company Size
Figure 7.3 Biologics Continuous Manufacturers: Distribution by Location of Headquarters
Figure 7.4 Biologics Continuous Manufacturers: Distribution by Type of Player
Figure 7.5 Biologics Continuous Manufacturers: Distribution by Scale of Operation
Figure 7.6 Biologics Continuous Manufacturers: Distribution by Type of Biologic Manufactured
Figure 7.7 Biologics Continuous Manufacturers: Distribution by Type of Product Manufactured
Figure 7.8 Biologics Continuous Manufacturers: Distribution by Location of Continuous Manufacturing Facilities
Figure 7.9 Biologics Continuous Manufacturers: Distribution by Type of Continuous Manufacturing Facility
Figure 7.10 Biologics Continuous Manufacturers: Distribution by Stage of Bioprocessing
Figure 7.11 Biologics Continuous Manufacturers: Distribution by Stage of Upstream Bioprocessing
Figure 7.12 Biologics Continuous Manufacturers: Distribution by Stage of Downstream Bioprocessing
Figure 7.13 Biologics Continuous Manufacturers: Distribution by Quality Certificates Obtained
Figure 7.14 Biologics Continuous Manufacturers: Distribution by Range of Installed Capacity (in Liters)
Figure 8.1 Company Competitiveness Analysis: Biologics Continuous Manufacturers based in North America
Figure 8.2 Company Competitiveness Analysis: Biologics Continuous Manufacturers based in Europe
Figure 8.3 Company Competitiveness Analysis: Biologics Continuous Manufacturers based in Asia-Pacific
Figure 9.1 Small Molecules Continuous Manufacturers: Distribution by Year of Establishment
Figure 9.2 Small Molecules Continuous Manufacturers: Distribution by Company Size
Figure 9.3 Small Molecules Continuous Manufacturers: Distribution by Location of Headquarters
Figure 9.4 Small Molecules Continuous Manufacturers: Distribution by Type of Player
Figure 9.5 Small Molecules Continuous Manufacturers: Distribution by Scale of Operation
Figure 9.6 Small Molecules Continuous Manufacturers: Distribution by Type of Dosage Form
Figure 9.7 Small Molecules Continuous Manufacturers: Distribution by Type of Product Manufactured
Figure 9.8 Small Molecules Continuous Manufacturers: Distribution by Location of Continuous Manufacturing Facilities
Figure 9.9 Small Molecules Continuous Manufacturers: Distribution by Type of Continuous Manufacturing Process
Figure 9.10 Small Molecules Continuous Manufacturers: Distribution by Stage of Continuous API Manufacturing
Figure 9.11 Small Molecules Continuous Manufacturers: Distribution by Stage of Continuous FDF Manufacturing
Figure 9.12 Small Molecules Continuous Manufacturers: Distribution by Quality Certificates Obtained
Figure 10.1 Company Competitiveness Analysis: Small Molecules Continuous Manufacturers based in North America
Figure 10.2 Company Competitiveness Analysis: Small Molecules Continuous Manufacturers based in Europe
Figure 10.3 Company Competitiveness Analysis: Small Molecules Continuous Manufacturer based in Asia-Pacific
Figure 11.1 AbbVie: Annual Revenues, Consolidated Financial Details, Since FY 2021 (USD Billion)
Figure 11.2 AGC Biologics: Annual Revenues, Consolidated Financial Details, Since FY 2021 (JPY Billion)
Figure 12.1 Boehringer Ingelheim: Annual Revenues, Consolidated Financial Details, Since FY 2021 (EUR Billion)
Figure 13.1 Kaneka: Annual Revenues, Consolidated Financial Details, Since FY 2021 (JPY Billion)
Figure 13.2 WuXi Biologics: Annual Revenues, Consolidated Financial Details, Since FY 2021 (RMB Billion)
Figure 14.1 Partnerships and Collaborations: Cumulative Year-wise Trend, Since Pre-2020
Figure 14.2 Partnerships and Collaborations: Distribution by Type of Partnership
Figure 14.3 Partnerships and Collaborations: Distribution by Year and Type of Partnership, Since Pre-2020
Figure 14.4 Partnerships and Collaborations: Distribution by Type of Partner
Figure 14.5 Partnerships and Collaborations: Distribution by Type of Drug Molecule
Figure 14.6 Partnerships and Collaborations: Distribution by Type of Product
Figure 14.7 Partnerships and Collaborations: Distribution by Scale of Operation
Figure 14.8 Most Active Players: Distribution by Number of Partnerships
Figure 14.9 Partnerships and Collaborations: Local and International Agreements
Figure 14.10 Partnerships and Collaborations: Intracontinental and Intercontinental Agreements
Figure 15.1 Recent Expansions: Cumulative Year-wise Trend, Since 2018
Figure 15.2 Recent Expansions: Distribution by Type of Expansion
Figure 15.3 Recent Expansions: Distribution by Year and Type of Expansion, Since 2018
Figure 15.4 Recent Expansions: Distribution by Scale of Operation
Figure 15.5 Recent Expansions: Distribution by Type of Expansion and Scale of Operation
Figure 15.6 Recent Expansions: Distribution by Type of Drug Molecule
Figure 15.7 Recent Expansions: Distribution by Type of Drug Molecule Manufactured and Type of Expansion
Figure 15.8 Recent Expansions: Distribution by Type of Product
Figure 15.9 Recent Expansions: Distribution by Amount Invested (USD Million)
Figure 15.10 Recent Expansions: Distribution by Facility Area (square feet)
Figure 15.11 Most Active Players: Distribution by Number of Expansions
Figure 15.12 Recent Expansions: Distribution by Location of Expansion (Country)
Figure 15.13 Recent Expansions: Distribution by Location of Expansion (Continent)
Figure 15.14 Recent Expansions: Distribution by Location of Expansion (Continent) and Type of Expansion
Figure 16.1 Grants Analysis: Cumulative Distribution by Year of Grant, Since 2020
Figure 16.2 Grants Analysis: Distribution by Cumulative Amount Awarded (USD Million), Since 2020
Figure 16.3 Grants Analysis: Distribution by Funding Institute Center
Figure 16.4 Grants Analysis: Distribution by Support Period
Figure 16.5 Grants Analysis: Distribution by Type of Grant Application
Figure 16.6 Grants Analysis: Distribution by Purpose of Grant Award
Figure 16.7 Grants Analysis: Distribution by Activity Code
Figure 16.8 Grants Analysis: Distribution by Study Section Involved
Figure 16.9 Popular NIH Departments: Distribution by Number of Grants
Figure 16.10 Grants Analysis: Distribution by Type of Recipient Organization
Figure 16.11 Prominent Program Officers: Distribution by Number of Grants
Figure 16.12 Popular Recipient Organizations: Distribution by Number of Grants
Figure 16.13 Popular Recipient Organizations: Distribution by Grant Amount (USD Million)
Figure 16.14 Grants Analysis: Distribution by Region of Recipient Organization
Figure 17.1 Patent Analysis: Distribution by Type of Patent
Figure 17.2 Patent Analysis: Cumulative Distribution by Patent Publication Year, Since 2020
Figure 17.3 Patent Analysis: Distribution by Type of Patent and Publication Year, Since 2020
Figure 17.4 Patent Analysis: Distribution by Patent Application Year, Since Pre-2019
Figure 17.5 Patent Analysis: Patent Jurisdiction
Figure 17.6 Patent Analysis: Distribution by CPC Symbols
Figure 17.7 Leading Industry Players: Distribution by Number of Patents
Figure 17.8 Leading Non-Industry Players: Distribution by Number of Patents
Figure 17.9 Patent Benchmarking Analysis: Distribution of Patent Characteristics (CPC Codes) by Leading Industry Players
Figure 17.10 Patent Benchmarking Analysis: Distribution of Leading Industry Players by Patent Characteristics (CPC Codes)
Figure 17.11 Patent Analysis: Distribution by Patent Age
Figure 17.12 Continuous Manufacturing: Patent Valuation
Figure 20.1 Biologics Continuous Manufacturing Equipment: Distribution by Type of Equipment
Figure 20.2 Biologics Continuous Manufacturing Equipment: Distribution by Type of Manufacturing Process
Figure 20.3 Biologics Continuous Manufacturing Equipment: Distribution by Stage of Bioprocessing
Figure 20.4 Biologics Continuous Manufacturing Equipment: Distribution by Scale of Operation
Figure 20.5 Biologics Continuous Manufacturing Equipment Providers: Distribution by Year of Establishment
Figure 20.6 Biologics Continuous Manufacturing Equipment Providers: Distribution by Company Size
Figure 20.7 Biologics Continuous Manufacturing Equipment Providers: Distribution by Location of Headquarters
Figure 20.8 Most Active Players: Distribution by Number of Biologics Continuous Manufacturing Equipment Offered
Figure 21.1 Continuous Manufacturing: Phase wise Key Strategies for the Adoption of Continuous Manufacturing Processes
Figure 21.2 Process Development and Implementation (Phase I): Distribution by Type of Strategy Adopted
Figure 21.3 Equipment / Technology Development and Installation (Phase II): Distribution by the Type of Strategy Adopted
Figure 21.4 Facility / Plant Development and Establishment (Phase III): Distribution by the Type of Strategy Adopted
Figure 21.5 Product Development and Manufacturing (Phase IV): Distribution by the Type of Strategy Adopted
Figure 22.1 Modular Construction: Applications
Figure 22.2 Steps Involved in Modular Construction
Figure 22.3 Construction Timeline of Modular and Conventional Buildings
Figure 22.4 Modular Construction: Advantages
Figure 22.5 Modular Facility Manufacturers: Distribution by Type of Industry Served
Figure 22.6 Modular Facility Manufacturers: Distribution by Geographical Coverage
Figure 22.7 Modular Facility Manufacturers: Distribution by Type of Modular Construction
Figure 22.8 Modular Cleanroom Providers: Distribution by Year of Establishment
Figure 22.9 Modular Cleanroom Providers: Distribution by Location of Headquarters
Figure 22.10 Modular Cleanroom Providers: Distribution of Headquarters (Country)
Figure 22.11 Modular Cleanroom Providers: Distribution by Type of Modular Cleanroom Offered
Figure 23.1 Global Installed Biologics Continuous Manufacturing Capacity: Distribution by Range of Installed Capacity (in Liters)
Figure 23.2 Global Installed Biologics Continuous Manufacturing Capacity (in Liters): Distribution by Company Size
Figure 23.3 Global Installed Biologics Continuous Manufacturing Capacity: Distribution by Scale of Operation
Figure 23.4 Global Installed Biologics Continuous Manufacturing Capacity: Distribution by Type of Player
Figure 23.5 Global Installed Biologics Continuous Manufacturing Capacity: Distribution by Location of Continuous Manufacturing Facility
Figure 23.6 Biologics Continuous Manufacturing Capacity Installed in North in North America
Figure 23.7 Biologics Continuous Manufacturing Capacity Installed in Europe
Figure 23.8 Biologics Continuous Manufacturing Capacity Installed in Asia-Pacific
Figure 24.1 Global Installed Continuous Small Molecule Manufacturing Capacity (in Kg/Year): Distribution by Range of Installed Capacity
Figure 24.2 Global Installed Continuous Small Molecule Manufacturing Capacity (in Kg/ Year): Distribution by Company Size
Figure 24.3 Global Installed Continuous Small Molecule Manufacturing Capacity (in Kg/ Year): Distribution by Scale of Operation
Figure 24.4 Global Continuous Small Molecule Manufacturing Capacity: Distribution by Type of Player
Figure 24.5 Global Installed Continuous Small Molecule Manufacturing Capacity: Distribution by Location of Continuous Manufacturing Facility
Figure 24.6 Continuous Small Molecule Manufacturing Capacity Installed in North America
Figure 24.7 Continuous Small Molecule Manufacturing Capacity Installed in Europe
Figure 24.8 Continuous Small Molecule Manufacturing Capacity Installed in Asia-Pacific
Figure 25.1 Global Continuous Manufacturing Market, Historical Trends (Since 2021) and Forecasted Estimates (Till 2035) (USD Million)
Figure 25.2 Global Continuous Manufacturing Market, Forecasted Estimates (Till 2035): Conservative Scenario (USD Million)
Figure 25.3 Global Continuous Manufacturing Market, Forecasted Estimates (Till 2035): Optimistic Scenario (USD Million)
Figure 26.1 Continuous Manufacturing Market: Distribution by Type of Drug Molecule, 2021, 2025 and 2035
Figure 26.2 Continuous Manufacturing Market for Biologics, Historical Trends (Since 2021) and Forecasted Estimates (Till 2035) (USD Million)
Figure 26.3 Biologics Continuous Manufacturing Market for Upstream Bioprocessing, Historical Trends (Since 2021) and Forecasted Estimates (Till 2035) (USD Million)
Figure 26.4 Biologics Continuous Manufacturing Market for Downstream Bioprocessing, Historical Trends (Since 2021) and Forecasted Estimates (Till 2035) (USD Million)
Figure 26.5 Continuous Manufacturing for Small Molecules Market, Historical Trends (Since 2021) and Forecasted Estimates (Till 2035) (USD Million)
Figure 26.6 Small Molecules Continuous Manufacturing Market for Active Pharmaceutical Ingredients, Historical Trends (Since 2021) and Forecasted Estimates (Till 2035) (USD Million)
Figure 26.7 Small Molecules Continuous Manufacturing Market for Finished Drug Forms, Historical Trends (Since 2021) and Forecasted Estimates (Till 2035) (USD Million)
Figure 27.1 Biologics Continuous Manufacturing Market: Distribution by Scale of Operation, 2021, 2025 and 2035
Figure 27.2 Biologics Continuous Manufacturing Market for Preclinical / Clinical Scale Operations, Historical Trends (Since 2021) and Forecasted Estimates (Till 2035) (USD Million)
Figure 27.3 Biologics Continuous Manufacturing Market for Commercial Scale Operations, Historical Trends (Since 2021) and Forecasted Estimates (Till 2035) (USD Million)
Figure 27.4 Small Molecules Continuous Manufacturing Market: Distribution by Scale of Operation, 2021, 2025 and 2035
Figure 27.5 Small Molecules Continuous Manufacturing Market for Preclinical / Clinical Scale Operations, Historical Trends (Since 2021) and Forecasted Estimates (Till 2035) (USD Million)
Figure 27.6 Small Molecules Continuous Manufacturing Market for Commercial Scale Operations, Historical Trends (Since 2021) and Forecasted Estimates (Till 2035) (USD Million)
Figure 28.1 Biologics Continuous Manufacturing Market: Distribution by Purpose of Manufacturing, 2021, 2025 and 2035
Figure 28.2 Biologics Continuous Manufacturing Market for Contract Manufacturing, Historical Trends (Since 2021) and Forecasted Estimates (Till 2035) (USD Million)
Figure 28.3 Biologics Continuous Manufacturing Market for In-House Manufacturing, Historical Trends (Since 2021) and Forecasted Estimates (Till 2035) (USD Million)
Figure 28.4 Biologics Continuous Manufacturing Market for Both, Historical Trends (Since 2021) and Forecasted Estimates (Till 2035) (USD Million)
Figure 28.5 Small Molecules Continuous Manufacturing Market: Distribution by Purpose of Manufacturing
Figure 28.6 Small Molecules Continuous Manufacturing Market for Contract Manufacturing, Historical Trends (Since 2021) and Forecasted Estimates (Till 2035) (USD Million)
Figure 28.7 Small Molecules Continuous Manufacturing Market for In-House Manufacturing, Historical Trends (Since 2021) and Forecasted Estimates (Till 2035) (USD Million)
Figure 28.8 Small Molecules Continuous Manufacturing Market for Both, Historical Trends (Since 2021) and Forecasted Estimates (Till 2035) (USD Million)
Figure 29.1 Biologics Continuous Manufacturing Market: Distribution by Company Size, 2021, 2025 and 2035
Figure 29.2 Biologics Continuous Manufacturing Market for Small Companies, Historical Trends (Since 2021) and Forecasted Estimates (Till 2035) (USD Million)
Figure 29.3 Biologics Continuous Manufacturing Market for Mid-Sized Companies, Historical Trends (Since 2021) and Forecasted Estimates (Till 2035) (USD Million)
Figure 29.4 Biologics Continuous Manufacturing Market for Large Companies, Historical Trends (Since 2021) and Forecasted Estimates (Till 2035) (USD Million)
Figure 29.5 Small Molecules Continuous Manufacturing Market: Distribution by Company Size, 2021, 2025 and 2035
Figure 29.6 Small Molecules Continuous Manufacturing Market for Small Companies, Historical Trends (Since 2021) and Forecasted Estimates (Till 2035) (USD Million)
Figure 29.7 Small Molecules Continuous Manufacturing Market for Mid-Sized Companies, Historical Trends (Since 2021) and Forecasted Estimates (Till 2035) (USD Million)
Figure 29.8 Small Molecules Continuous Manufacturing Market for Large Companies, Historical Trends (Since 2021) and Forecasted Estimates (Till 2035) (USD Million)
Figure 30.1 Biologics Continuous Manufacturing Market: Distribution by Key Geographical Regions, 2021, 2025 and 2035
Figure 30.2 Biologics Continuous Manufacturing Market in North America: Historical Trends (Since 2021) and Forecasted Estimates (Till 2035) (USD Million)
Figure 30.3 Biologics Continuous Manufacturing Market in the US: Historical Trends (Since 2021) and Forecasted Estimates (Till 2035) (USD Million)
Figure 30.4 Biologics Continuous Manufacturing Market in Puerto Rico: Historical Trends (Since 2021) and Forecasted Estimates (Till 2035) (USD Million)
Figure 30.5 Biologics Continuous Manufacturing Market in Europe: Historical Trends (Since 2021) and Forecasted Estimates (Till 2035) (USD Million)
Figure 30.6 Biologics Continuous Manufacturing Market in Germany: Historical Trends (Since 2021) and Forecasted Estimates (Till 2035) (USD Million)
Figure 30.7 Biologics Continuous Manufacturing Market in Switzerland: Historical Trends (Since 2021) and Forecasted Estimates (Till 2035) (USD Million)
Figure 30.8 Biologics Continuous Manufacturing Market in Belgium: Historical Trends (Since 2021) and Forecasted Estimates (Till 2035) (USD Million)
Figure 30.9 Biologics Continuous Manufacturing Market in Ireland: Historical Trends (Since 2021) and Forecasted Estimates (Till 2035) (USD Million)
Figure 30.10 Biologics Continuous Manufacturing Market in France: Historical Trends (Since 2021) and Forecasted Estimates (Till 2035) (USD Million)
Figure 30.11 Biologics Continuous Manufacturing Market in Rest of Europe: Historical Trends (Since 2021) and Forecasted Estimates (Till 2035) (USD Million)
Figure 30.12 Biologics Continuous Manufacturing Market in Asia-Pacific: Historical Trends (Since 2021) and Forecasted Estimates (Till 2035) (USD Million)
Figure 30.13 Biologics Continuous Manufacturing Market in China: Historical Trends (Since 2021) and Forecasted Estimates (Till 2035) (USD Million)
Figure 30.14 Biologics Continuous Manufacturing Market in South Korea: Historical Trends (Since 2021) and Forecasted Estimates (Till 2035) (USD Million)
Figure 30.15 Biologics Continuous Manufacturing Market in Singapore: Historical Trends (Since 2021) and Forecasted Estimates (Till 2035) (USD Million)
Figure 30.16 Biologics Continuous Manufacturing Market in Taiwan: Historical Trends (Since 2021) and Forecasted Estimates (Till 2035) (USD Million)
Figure 30.17 Biologics Continuous Manufacturing Market in India: Historical Trends (Since 2021) and Forecasted Estimates (Till 2035) (USD Million)
Figure 30.18 Biologics Continuous Manufacturing Market in Japan: Historical Trends (Since 2021) and Forecasted Estimates (Till 2035) (USD Million)
Figure 30.19 Biologics Continuous Manufacturing Market in Australia: Historical Trends (Since 2021) and Forecasted Estimates (Till 2035) (USD Million)
Figure 30.20 Biologics Continuous Manufacturing Market: Market Movement Analysis
Figure 30.21 Biologics Continuous Manufacturing Market: Penetration Growth (P-G) Matrix
Figure 30.22 Small Molecules Continuous Manufacturing Market: Distribution by Key Geographical Regions, 2021, 2025 and 2035
Figure 30.23 Small Molecules Continuous Manufacturing Market in North America: Historical Trends (Since 2021) and Forecasted Estimates (Till 2035) (USD Million)
Figure 30.24 Small Molecules Continuous Manufacturing Market in the US: Historical Trends (Since 2021) and Forecasted Estimates (Till 2035) (USD Million)
Figure 30.25 Small Molecules Continuous Manufacturing Market in Mexico: Historical Trends (Since 2021) and Forecasted Estimates (Till 2035) (USD Million)
Figure 30.26 Small Molecules Continuous Manufacturing Market in Europe: Historical Trends (Since 2021) and Forecasted Estimates (Till 2035) (USD Million)
Figure 30.27 Small Molecules Continuous Manufacturing Market in Germany: Historical Trends (Since 2021) and Forecasted Estimates (Till 2035) (USD Million)
Figure 30.28 Small Molecules Continuous Manufacturing Market in the UK: Historical Trends (Since 2021) and Forecasted Estimates (Till 2035) (USD Million)
Figure 30.29 Small Molecules Continuous Manufacturing Market in Italy: Historical Trends (Since 2021) and Forecasted Estimates (Till 2035) (USD Million)
Figure 30.30 Small Molecules Continuous Manufacturing Market in Switzerland: Historical Trends (Since 2021) and Forecasted Estimates (Till 2035) (USD Million)
Figure 30.31 Small Molecules Continuous Manufacturing Market in France: Historical Trends (Since 2021) and Forecasted Estimates (Till 2035) (USD Million)
Figure 30.32 Small Molecules Continuous Manufacturing Market in Belgium: Historical Trends (Since 2021) and Forecasted Estimates (Till 2035) (USD Million)
Figure 30.33 Small Molecules Continuous Manufacturing Market in Rest of Europe: Historical Trends (Since 2021) and Forecasted Estimates (Till 2035) (USD Million)
Figure 30.34 Small Molecules Continuous Manufacturing Market in Asia-Pacific: Historical Trends (Since 2021) and Forecasted Estimates (Till 2035) (USD Million)
Figure 30.35 Small Molecules Continuous Manufacturing Market in China: Historical Trends (Since 2021) and Forecasted Estimates (Till 2035) (USD Million)
Figure 30.36 Small Molecules Continuous Manufacturing Market in Singapore: Historical Trends (Since 2021) and Forecasted Estimates (Till 2035) (USD Million)
Figure 30.37 Small Molecules Continuous Manufacturing Market in Japan: Historical Trends (Since 2021) and Forecasted Estimates (Till 2035) (USD Million)
Figure 30.38 Small Molecules Continuous Manufacturing Market in India: Historical Trends (Since 2021) and Forecasted Estimates (Till 2035) (USD Million)
Figure 30.39 Small Molecules Continuous Manufacturing Market in South Korea: Historical Trends (Since 2021) and Forecasted Estimates (Till 2035) (USD Million)
Figure 34.1 Concluding Remarks: Market Landscape (Biologics Continuous Manufacturing)
Figure 34.2 Concluding Remarks: Market Landscape (Small Molecules Continuous Manufacturing)
Figure 34.3 Concluding Remarks: Partnerships and Collaboration
Figure 34.4 Concluding Remarks: Recent Expansions
Figure 34.5 Concluding Remarks: Grant Analysis
Figure 34.6 Concluding Remarks: Patent Analysis
Figure 34.7 Concluding Remarks: Capacity Analysis
Figure 34.8 Concluding Remarks: Market Forecast and Opportunity Analysis (Biologics Continuous Manufacturing)
Figure 34.9 Concluding Remarks: Market Forecast and Opportunity Analysis (Small Molecules Continuous Manufacturing)

List of Tables

Table 6.1 Comparison of Batch and Continuous Manufacturing Techniques
Table 7.1 Biologics Continuous Manufacturers: Information on Year of Establishment, Employee Count, Company Size and Location of Headquarters
Table 7.2 Biologics Continuous Manufacturers: Information on Scale of Operation, Type of Player, Type of Biologic Manufactured and Type of Product Manufactured
Table 7.3 Biologics Continuous Manufacturers: Information on Number of Continuous Manufacturing Facilities, Location of the Continuous Manufacturing Facilities and Type of Facility
Table 7.4 Biologics Continuous Manufacturers: Information on Stage of Bioprocessing, Stage of Upstream Bioprocessing and Stage of Downstream Bioprocessing
Table 7.5 Biologics Continuous Manufacturers: Information on Type of Upstream Manufacturing Process, Type of Downstream Manufacturing Process, Type of Overall Manufacturing Process and Quality Certificates Obtained
Table 7.6 Biologics Continuous Manufacturers: Information on Location of Continuous Manufacturing Facility and Installed Capacity
Table 9.1 Small Molecules Continuous Manufacturers: Information on Year of Establishment, Employee Count, Company Size and Location of Headquarters
Table 9.2 Small Molecules Continuous Manufacturers: Information on Scale of Operation, Type of Player, Type of Dosage Form and Type of Product Manufactured
Table 9.3 Small Molecules Continuous Manufacturers: Information on Number of Continuous Manufacturing Facilities and Location of Continuous Manufacturing Facilities
Table 9.4 Small Molecules Continuous Manufacturers: Information on Stage of Continuous API Manufacturing and Stage of Continuous FDF Manufacturing
Table 9.5 Small Molecules Continuous Manufacturers: Information on Type of API Manufacturing Process, Type of FDF Manufacturing Process and Quality Certificates Obtained
Table 11.1 Continuous Manufacturing Market: List of Service Providers based in North America
Table 11.2 AbbVie Contract Manufacturing: Company Overview
Table 11.3 AbbVie Contract Manufacturing: Continuous Manufacturing Service Portfolio
Table 11.4 AbbVie Contract Manufacturing: Continuous Manufacturing Facilities
Table 11.5 Abzena: Company Overview
Table 11.6 Abzena: Continuous Manufacturing Service Portfolio
Table 11.7 Abzena: Continuous Manufacturing Facilities
Table 11.8 Abzena: Recent Developments and Future Outlook
Table 11.9 AGC Biologics: Company Overview
Table 11.10 AGC Biologics: Continuous Manufacturing Service Portfolio
Table 11.11 AGC Biologics: Continuous Manufacturing Facilities
Table 11.12 AGC Biologics: Recent Developments and Future Outlook
Table 11.13 Phlow: Company Overview
Table 11.14 Phlow: Continuous Manufacturing Service Portfolio
Table 11.15 Phlow: Continuous Manufacturing Facilities
Table 11.16 Phlow: Recent Developments and Future Outlook
Table 12.1 Continuous Manufacturing Market: List of Service Providers based in Europe
Table 12.2 Boehringer Ingelheim: Company Overview
Table 12.3 Boehringer Ingelheim: Continuous Manufacturing Service Portfolio
Table 12.4 Boehringer Ingelheim: Continuous Manufacturing Facilities
Table 12.5 Boehringer Ingelheim: Recent Developments and Future Outlook
Table 12.6 Corden Pharma: Company Overview
Table 12.7 Corden Pharma: Continuous Manufacturing Service Portfolio
Table 12.8 Corden Pharma: Continuous Manufacturing Facilities
Table 12.9 Corden Pharma: Recent Developments and Future Outlook
Table 12.10 Glatt: Company Overview
Table 12.11 Glatt: Continuous Manufacturing Service Portfolio
Table 12.12 Glatt: Continuous Manufacturing Facilities
Table 13.1 Continuous Manufacturing Market: List of Service Providers based in Asia-Pacific
Table 13.2 Kaneka: Company Overview
Table 13.3 Kaneka: Continuous Manufacturing Service Portfolio
Table 13.4 Kaneka: Continuous Manufacturing Facilities
Table 13.5 WuXi Biologics: Company Overview
Table 13.6 WuXi Biologics: Continuous Manufacturing Service Portfolio
Table 13.7 WuXi Biologics: Continuous Manufacturing Facilities
Table 13.8 WuXi Biologics: Recent Developments and Future Outlook
Table 14.1 Continuous Manufacturing Market: List of Partnerships and Collaborations, Since Pre-2020
Table 14.2 Partnerships and Collaborations: Information on Type of Agreement (Country-wise and Region-wise)
Table 15.1 Continuous Manufacturing Market: List of Recent Expansions, Since 2018
Table 17.1 Patent Analysis: Top CPC Sections 
Table 17.2 Patent Analysis: Top CPC Symbols
Table 17.3 Patent Analysis: Top CPC Codes
Table 17.4 Patent Analysis: Summary of Benchmarking Analysis
Table 17.5 Patent Analysis: Categorization based on Weighted Valuation Scores
Table 17.6 Patent Portfolio: List of Leading Patents (by Highest Relative Valuation)
Table 17.7 Patent Portfolio: List of Leading Patents (by Number of Citations)
Table 18.1 Overall Gaps and Opportunities Associated with Continuous Manufacturing
Table 19.1 Amgen: In-House Initiatives
Table 19.2 Boehringer Ingelheim: In-House Initiatives
Table 19.3 Bristol-Myers Squibb: In-House Initiatives
Table 19.4 Bristol-Myers Squibb: Partnered Initiatives
Table 19.5 GSK: In-House Initiatives
Table 19.6 GSK: Partnered Initiatives
Table 19.7 Merck: In-House Initiatives
Table 19.8 Merck: Partnered Initiatives
Table 19.9 Novartis: In-House Initiatives
Table 19.10 Novartis: Partnered Initiatives
Table 19.11 Pfizer: In-House Initiatives
Table 19.12 Pfizer: Partnered Initiatives
Table 19.13 Sanofi: In-House Initiatives
Table 19.14 Sanofi: Partnered Initiatives
Table 20.1 Biologics Continuous Manufacturing Equipment: Information on Developer, Type of Equipment, Manufacturing Process, Stage of Bioprocessing and Scale of Operation
Table 20.2 Biologics Continuous Manufacturing Equipment: List of Developers
Table 22.1 Modular Facility Manufacturers: Information on Year of Establishment, Company Size and Location of Headquarters
Table 22.2 Cleanroom Classification Standards
Table 22.3 ISO and FED STD 209E: Cleanroom Classification
Table 22.4 Modular Cleanroom Providers: Information on Year of Establishment, Company Size and Location of Headquarters
Table 23.1 Biologics Continuous Manufacturers: Information on Total Installed Capacity (Sample Data Set)
Table 23.2 Capacity Analysis: Average Continuous Biologics Manufacturing Capacity by Company Size (Sample Dataset)
Table 23.3 Global Installed Continuous Bioprocessing Capacity by Company Size (in Liters)
Table 24.1 Small Molecules Continuous Manufacturers: Information on Total Installed Capacity (Sample Data Set)
Table 24.2 Capacity Analysis: Average Continuous Small Molecule Manufacturing Capacity by Company Size (Sample Dataset)
Table 24.3 Annual, Global Installed Continuous Small Molecule Manufacturing Capacity (Kg/Year) by Company Size
Table 36.1 Biologics Continuous Manufacturers: Distribution by Year of Establishment
Table 36.2 Biologics Continuous Manufacturers: Distribution by Company Size
Table 36.3 Biologics Continuous Manufacturers: Distribution by Location of Headquarters
Table 36.4 Biologics Continuous Manufacturers: Distribution by Type of Player
Table 36.5 Biologics Continuous Manufacturers: Distribution by Scale of Operation
Table 36.6 Biologics Continuous Manufacturers: Distribution by Type of Biologic Manufactured
Table 36.7 Biologics Continuous Manufacturers: Distribution by Type of Product Manufactured
Table 36.8 Biologics Continuous Manufacturers: Distribution by Location of Continuous Manufacturing Facilities
Table 36.9 Biologics Continuous Manufacturers: Distribution by Type of Continuous Manufacturing Facility
Table 36.10 Biologics Continuous Manufacturers: Distribution by Stage of Bioprocessing
Table 36.11 Biologics Continuous Manufacturers: Distribution by Stage of Upstream Bioprocessing
Table 36.12 Biologics Continuous Manufacturers: Distribution by Stage of Downstream Bioprocessing
Table 36.13 Biologics Continuous Manufacturers: Distribution by Quality Certificates Obtained
Table 36.14 Biologics Continuous Manufacturers: Distribution by Range of Installed Capacity (in Liters)
Table 36.15 Small Molecules Continuous Manufacturers: Distribution by Year of Establishment
Table 36.16 Small Molecules Continuous Manufacturers: Distribution by Company Size
Table 36.17 Small Molecules Continuous Manufacturers: Distribution by Location of Headquarters
Table 36.18 Small Molecules Continuous Manufacturers: Distribution by Type of Player
Table 36.19 Small Molecules Continuous Manufacturers: Distribution by Scale of Operation
Table 36.20 Small Molecules Continuous Manufacturers: Distribution by Type of Dosage Form
Table 36.21 Small Molecules Continuous Manufacturers: Distribution by Type of Product Manufactured
Table 36.22 Small Molecules Continuous Manufacturers: Distribution by Location of Continuous Manufacturing Facilities
Table 36.23 Small Molecules Continuous Manufacturers: Distribution by Type of Continuous Manufacturing Process
Table 36.24 Small Molecules Continuous Manufacturers: Distribution by Stage of Continuous API Manufacturing
Table 36.25 Small Molecules Continuous Manufacturers: Distribution by Stage of Continuous FDF Manufacturing
Table 36.26 Small Molecules Continuous Manufacturers: Distribution by Quality Certificates Obtained
Table 36.27 AbbVie: Annual Revenues, Consolidated Financial Details, Since FY 2021 (USD Billion)
Table 36.28 AGC Biologics: Annual Revenues, Consolidated Financial Details, Since FY 2021 (JPY Billion)
Table 36.29 Boehringer Ingelheim: Annual Revenues, Consolidated Financial Details, Since FY 2021 (EUR Billion)
Table 36.30 Kaneka: Annual Revenues, Consolidated Financial Details, Since FY 2021 (JPY Billion)
Table 36.31 WuXi Biologics: Annual Revenues, Consolidated Financial Details, Since FY 2021 (RMB Billion)
Table 36.32 Partnerships and Collaborations: Cumulative Year-wise Trend, Since Pre-2020
Table 36.33 Partnerships and Collaborations: Distribution by Type of Partnership
Table 36.34 Partnerships and Collaborations: Distribution by Year and Type of Partnership, Since Pre-2020
Table 36.35 Partnerships and Collaborations: Distribution by Type of Partner
Table 36.36 Partnerships and Collaborations: Distribution by Type of Drug Molecule
Table 36.37 Partnerships and Collaborations: Distribution by Type of Product
Table 36.38 Partnerships and Collaborations: Distribution by Scale of Operation
Table 36.39 Most Active Players: Distribution by Number of Partnerships
Table 36.40 Partnerships and Collaborations: Local and International Agreements
Table 36.41 Partnerships and Collaborations: Intracontinental and Intercontinental Agreements
Table 36.42 Recent Expansions: Cumulative Year-wise Trend, Since 2018
Table 36.43 Recent Expansions: Distribution by Type of Expansion
Table 36.44 Recent Expansions: Distribution by Year and Type of Expansion, Since 2018
Table 36.45 Recent Expansions: Distribution by Scale of Operation
Table 36.46 Recent Expansions: Distribution by Type of Expansion and Scale of Operation
Table 36.47 Recent Expansions: Distribution by Type of Drug Molecule
Table 36.48 Recent Expansions: Distribution by Type of Drug Molecule Manufactured and Type of Expansion
Table 36.49 Recent Expansions: Distribution by Type of Product
Table 36.50 Recent Expansions: Distribution by Amount Invested (USD Million)
Table 36.51 Recent Expansions: Distribution by Facility Area (square feet)
Table 36.52 Most Active Players: Distribution by Number of Expansions
Table 36.53 Recent Expansions: Distribution by Location of Expansion (Country)
Table 36.54 Recent Expansions: Distribution by Location of Expansion (Continent)
Table 36.55 Recent Expansions: Distribution by Location of Expansion (Continent) and Type of Expansion
Table 36.56 Grants Analysis: Cumulative Distribution by Year of Grant, Since 2020
Table 36.57 Grants Analysis: Distribution by Cumulative Amount Awarded (USD Million), Since 2020
Table 36.58 Grants Analysis: Distribution by Funding Institute Center
Table 36.59 Grants Analysis: Distribution by Support Period
Table 36.60 Grants Analysis: Distribution by Type of Grant Application
Table 36.61 Grants Analysis: Distribution by Purpose of Grant Award
Table 36.62 Grants Analysis: Distribution by Activity Code
Table 36.63 Grants Analysis: Distribution by Study Section Involved
Table 36.64 Popular NIH Departments: Distribution by Number of Grants
Table 36.65 Grants Analysis: Distribution by Type of Recipient Organization
Table 36.66 Prominent Program Officers: Distribution by Number of Grants
Table 36.67 Popular Recipient Organizations: Distribution by Number of Grants
Table 36.68 Popular Recipient Organizations: Distribution by Grant Amount (USD Million)
Table 36.69 Grants Analysis: Distribution by Region of Recipient Organization
Table 36.70 Patent Analysis: Distribution by Type of Patent
Table 36.71 Patent Analysis: Cumulative Distribution by Patent Publication Year, Since 2020
Table 36.72 Patent Analysis: Distribution by Type of Patent and Publication Year, Since 2020
Table 36.73 Patent Analysis: Distribution by Patent Application Year, Since Pre-2019
Table 36.74 Patent Analysis: Patent Jurisdiction
Table 36.75 Leading Industry Players: Distribution by Number of Patents
Table 36.76 Leading Non-Industry Players: Distribution by Number of Patents
Table 36.77 Patent Analysis: Distribution by Patent Age
Table 36.78 Continuous Manufacturing: Patent Valuation
Table 36.79 Biologics Continuous Manufacturing Equipment: Distribution by Type of Equipment
Table 36.80 Biologics Continuous Manufacturing Equipment: Distribution by Type of Manufacturing Process
Table 36.81 Biologics Continuous Manufacturing Equipment: Distribution by Stage of Bioprocessing
Table 36.82 Biologics Continuous Manufacturing Equipment: Distribution by Scale of Operation
Table 36.83 Biologics Continuous Manufacturing Equipment Providers: Distribution by Year of Establishment
Table 36.84 Biologics Continuous Manufacturing Equipment Providers: Distribution by Company Size
Table 36.85 Biologics Continuous Manufacturing Equipment Providers: Distribution by Location of Headquarters
Table 36.86 Most Active Players: Distribution by Number of Biologics Continuous Manufacturing Equipment Offered
Table 36.87 Continuous Manufacturing: Phase wise Key Strategies for the Adoption of Continuous Manufacturing Processes
Table 36.88 Process Development and Implementation (Phase I): Distribution by Type of Strategy Adopted
Table 36.89 Equipment / Technology Development and Installation (Phase II): Distribution by the Type of Strategy Adopted
Table 36.90 Facility / Plant Development and Establishment (Phase III): Distribution by the Type of Strategy Adopted
Table 36.91 Product Development and Manufacturing (Phase IV): Distribution by the Type of Strategy Adopted
Table 36.92 Modular Construction: Applications
Table 36.93 Steps Involved in Modular Construction
Table 36.94 Construction Timeline of Modular and Conventional Buildings
Table 36.95 Modular Construction: Advantages
Table 36.96 Modular Facility Manufacturers: Distribution by Type of Industry Served
Table 36.97 Modular Facility Manufacturers: Distribution by Geographical Coverage
Table 36.98 Modular Facility Manufacturers: Distribution by Type of Modular Construction
Table 36.99 Modular Cleanroom Providers: Distribution by Year of Establishment
Table 36.100 Modular Cleanroom Providers: Distribution by Location of Headquarters
Table 36.101 Modular Cleanroom Providers: Distribution of Headquarters (Country)
Table 36.102 Modular Cleanroom Providers: Distribution by Type of Modular Cleanroom Offered
Table 36.103 Global Installed Continuous Bioprocessing Capacity: Distribution by Range of Installed Capacity (in Liters)
Table 36.104 Global Installed Continuous Bioprocessing Capacity (in Liters): Distribution by Company Size
Table 36.105 Global Installed Continuous Bioprocessing Capacity: Distribution by Scale of Operation
Table 36.106 Global Installed Continuous Bioprocessing Capacity: Distribution by Type of Player
Table 36.107 Global Installed Continuous Bioprocessing Capacity: Distribution by Location of Continuous Manufacturing Facility
Table 36.108 Continuous Bioprocessing Capacity Installed in North in North America
Table 36.109 Continuous Bioprocessing Capacity Installed in Europe
Table 36.110 Continuous Bioprocessing Capacity Installed in Asia-Pacific
Table 36.111 Global Installed Continuous Small Molecule Manufacturing Capacity (Kg/Year): Distribution by Range of Installed Capacity
Table 36.112 Global Installed Continuous Small Molecule Manufacturing Capacity (Kg/ Year): Distribution by Company Size
Table 36.113 Global Installed Continuous Small Molecule Manufacturing Capacity (Kg/ Year): Distribution by Scale of Operation
Table 36.114 Global Continuous Small Molecule Manufacturing Capacity: Distribution by Type of Player
Table 36.115 Global Installed Continuous Small Molecule Manufacturing Capacity: Distribution by Location of Continuous Manufacturing Facility
Table 36.116 Continuous Small Molecule Manufacturing Capacity Installed in North America
Table 36.117 Continuous Small Molecule Manufacturing Capacity Installed in Europe
Table 36.118 Continuous Small Molecule Manufacturing Capacity Installed in Asia-Pacific
Table 36.119 Global Continuous Manufacturing Market, Historical Trends (Since 2021) and Forecasted Estimates (Till 2035) (USD Million)
Table 36.120 Global Continuous Manufacturing Market, Forecasted Estimates (Till 2035): Conservative Scenario (USD Million)
Table 36.121 Global Continuous Manufacturing Market, Forecasted Estimates (Till 2035): Optimistic Scenario (USD Million)
Table 36.122 Continuous Manufacturing Market: Distribution by Type of Drug Molecule, 2021, 2025 and 2035
Table 36.123 Continuous Manufacturing Market for Biologics, Historical Trends (Since 2021) and Forecasted Estimates (Till 2035) (USD Million): Conservative, Base and Optimistic Scenarios (USD Billion)
Table 36.124 Biologics Continuous Manufacturing Market for Upstream Bioprocessing, Historical Trends (Since 2021) and Forecasted Estimates (Till 2035) (USD Million): Conservative, Base and Optimistic Scenarios (USD Billion)
Table 36.125 Biologics Continuous Manufacturing Market for Downstream Bioprocessing, Historical Trends (Since 2021) and Forecasted Estimates (Till 2035) (USD Million): Conservative, Base and Optimistic Scenarios (USD Billion)
Table 36.126 Continuous Manufacturing for Small Molecules Market, Historical Trends (Since 2021) and Forecasted Estimates (Till 2035) (USD Million): Conservative, Base and Optimistic Scenarios (USD Billion)
Table 36.127 Small Molecules Continuous Manufacturing Market for Active Pharmaceutical Ingredients, Historical Trends (Since 2021) and Forecasted Estimates (Till 2035) (USD Million): Conservative, Base and Optimistic Scenarios (USD Billion)
Table 36.128 Small Molecules Continuous Manufacturing Market for Finished Drug Forms, Historical Trends (Since 2021) and Forecasted Estimates (Till 2035) (USD Million): Conservative, Base and Optimistic Scenarios (USD Billion)
Table 36.129 Biologics Continuous Manufacturing Market: Distribution by Scale of Operation, 2021, 2025 and 2035
Table 36.130 Biologics Continuous Manufacturing Market for Preclinical / Clinical Scale Operations, Historical Trends (Since 2021) and Forecasted Estimates (Till 2035) (USD Million): Conservative, Base and Optimistic Scenarios (USD Billion)
Table 36.131 Biologics Continuous Manufacturing Market for Commercial Scale Operations, Historical Trends (Since 2021) and Forecasted Estimates (Till 2035) (USD Million): Conservative, Base and Optimistic Scenarios (USD Billion)
Table 36.132 Small Molecules Continuous Manufacturing Market: Distribution by Scale of Operation, 2021, 2025 and 2035
Table 36.133 Small Molecules Continuous Manufacturing Market for Preclinical / Clinical Scale Operations, Historical Trends (Since 2021) and Forecasted Estimates (Till 2035) (USD Million): Conservative, Base and Optimistic Scenarios (USD Billion)
Table 36.134 Small Molecules Continuous Manufacturing Market for Commercial Scale Operations, Historical Trends (Since 2021) and Forecasted Estimates (Till 2035) (USD Million): Conservative, Base and Optimistic Scenarios (USD Billion)
Table 36.135 Biologics Continuous Manufacturing Market: Distribution by Purpose of Manufacturing, 2021, 2025 and 2035
Table 36.136 Biologics Continuous Manufacturing Market for Contract Manufacturing, Historical Trends (Since 2021) and Forecasted Estimates (Till 2035) (USD Million): Conservative, Base and Optimistic Scenarios (USD Billion)
Table 36.137 Biologics Continuous Manufacturing Market for In-House Manufacturing, Historical Trends (Since 2021) and Forecasted Estimates (Till 2035) (USD Million): Conservative, Base and Optimistic Scenarios (USD Billion)
Table 36.138 Biologics Continuous Manufacturing Market for Both, Historical Trends (Since 2021) and Forecasted Estimates (Till 2035) (USD Million): Conservative, Base and Optimistic Scenarios (USD Billion)
Table 36.139 Small Molecules Continuous Manufacturing Market: Distribution by Purpose of Manufacturing, 2021, 2025 and 2035
Table 36.140 Small Molecules Continuous Manufacturing Market for Contract Manufacturing, Historical Trends (Since 2021) and Forecasted Estimates (Till 2035) (USD Million): Conservative, Base and Optimistic Scenarios (USD Billion)
Table 36.141 Small Molecules Continuous Manufacturing Market for In-House Manufacturing, Historical Trends (Since 2021) and Forecasted Estimates (Till 2035) (USD Million): Conservative, Base and Optimistic Scenarios (USD Billion)
Table 36.142 Small Molecules Continuous Manufacturing Market for Both, Historical Trends (Since 2021) and Forecasted Estimates (Till 2035) (USD Million): Conservative, Base and Optimistic Scenarios (USD Billion)
Table 36.143 Biologics Continuous Manufacturing Market: Distribution by Company Size, 2021, 2025 and 2035
Table 36.144 Biologics Continuous Manufacturing Market for Small Companies, Historical Trends (Since 2021) and Forecasted Estimates (Till 2035) (USD Million): Conservative, Base and Optimistic Scenarios (USD Billion)
Table 36.145 Biologics Continuous Manufacturing Market for Mid-Sized Companies, Historical Trends (Since 2021) and Forecasted Estimates (Till 2035) (USD Million): Conservative, Base and Optimistic Scenarios (USD Billion)
Table 36.146 Biologics Continuous Manufacturing Market for Large Companies, Historical Trends (Since 2021) and Forecasted Estimates (Till 2035) (USD Million): Conservative, Base and Optimistic Scenarios (USD Billion)
Table 36.147 Small Molecules Continuous Manufacturing Market: Distribution by Company Size, 2021, 2025 and 2035
Table 36.148 Small Molecules Continuous Manufacturing Market for Small Companies, Historical Trends (Since 2021) and Forecasted Estimates (Till 2035) (USD Million): Conservative, Base and Optimistic Scenarios (USD Billion)
Table 36.149 Small Molecules Continuous Manufacturing Market for Mid-Sized Companies, Historical Trends (Since 2021) and Forecasted Estimates (Till 2035) (USD Million): Conservative, Base and Optimistic Scenarios (USD Billion)
Table 36.150 Small Molecules Continuous Manufacturing Market for Large Companies, Historical Trends (Since 2021) and Forecasted Estimates (Till 2035) (USD Million): Conservative, Base and Optimistic Scenarios (USD Billion)
Table 36.151 Biologics Continuous Manufacturing Market: Distribution by Key Geographical Regions, 2021, 2025 and 2035
Table 36.152 Biologics Continuous Manufacturing Market in North America: Historical Trends (Since 2021) and Forecasted Estimates (Till 2035) (USD Million): Conservative, Base and Optimistic Scenarios (USD Billion)
Table 36.153 Biologics Continuous Manufacturing Market in the US: Historical Trends (Since 2021) and Forecasted Estimates (Till 2035) (USD Million): Conservative, Base and Optimistic Scenarios (USD Billion)
Table 36.154 Biologics Continuous Manufacturing Market in Puerto Rico: Historical Trends (Since 2021) and Forecasted Estimates (Till 2035) (USD Million): Conservative, Base and Optimistic Scenarios (USD Billion)
Table 36.155 Biologics Continuous Manufacturing Market in Europe: Historical Trends (Since 2021) and Forecasted Estimates (Till 2035) (USD Million): Conservative, Base and Optimistic Scenarios (USD Billion)
Table 36.156 Biologics Continuous Manufacturing Market in Germany: Historical Trends (Since 2021) and Forecasted Estimates (Till 2035) (USD Million): Conservative, Base and Optimistic Scenarios (USD Billion)
Table 36.157 Biologics Continuous Manufacturing Market in Switzerland: Historical Trends (Since 2021) and Forecasted Estimates (Till 2035) (USD Million): Conservative, Base and Optimistic Scenarios (USD Billion)
Table 36.158 Biologics Continuous Manufacturing Market in Belgium: Historical Trends (Since 2021) and Forecasted Estimates (Till 2035) (USD Million): Conservative, Base and Optimistic Scenarios (USD Billion)
Table 36.159 Biologics Continuous Manufacturing Market in Ireland: Historical Trends (Since 2021) and Forecasted Estimates (Till 2035) (USD Million): Conservative, Base and Optimistic Scenarios (USD Billion)
Table 36.160 Biologics Continuous Manufacturing Market in France: Historical Trends (Since 2021) and Forecasted Estimates (Till 2035) (USD Million): Conservative, Base and Optimistic Scenarios (USD Billion)
Table 36.161 Biologics Continuous Manufacturing Market in Rest of Europe: Historical Trends (Since 2021) and Forecasted Estimates (Till 2035) (USD Million): Conservative, Base and Optimistic Scenarios (USD Billion)
Table 36.162 Biologics Continuous Manufacturing Market in Asia-Pacific: Historical Trends (Since 2021) and Forecasted Estimates (Till 2035) (USD Million): Conservative, Base and Optimistic Scenarios (USD Billion)
Table 36.163 Biologics Continuous Manufacturing Market in China: Historical Trends (Since 2021) and Forecasted Estimates (Till 2035) (USD Million): Conservative, Base and Optimistic Scenarios (USD Billion)
Table 36.164 Biologics Continuous Manufacturing Market in South Korea: Historical Trends (Since 2021) and Forecasted Estimates (Till 2035) (USD Million): Conservative, Base and Optimistic Scenarios (USD Billion)
Table 36.165 Biologics Continuous Manufacturing Market in Singapore: Historical Trends (Since 2021) and Forecasted Estimates (Till 2035) (USD Million): Conservative, Base and Optimistic Scenarios (USD Billion)
Table 36.166 Biologics Continuous Manufacturing Market in Taiwan: Historical Trends (Since 2021) and Forecasted Estimates (Till 2035) (USD Million): Conservative, Base and Optimistic Scenarios (USD Billion)
Table 36.167 Biologics Continuous Manufacturing Market in India: Historical Trends (Since 2021) and Forecasted Estimates (Till 2035) (USD Million): Conservative, Base and Optimistic Scenarios (USD Billion)
Table 36.168 Biologics Continuous Manufacturing Market in Japan: Historical Trends (Since 2021) and Forecasted Estimates (Till 2035) (USD Million): Conservative, Base and Optimistic Scenarios (USD Billion)
Table 36.169 Biologics Continuous Manufacturing Market in Australia: Historical Trends (Since 2021) and Forecasted Estimates (Till 2035) (USD Million): Conservative, Base and Optimistic Scenarios (USD Billion)
Table 36.170 Biologics Continuous Manufacturing Market: Market Movement Analysis
Table 36.171 Biologics Continuous Manufacturing Market: Penetration Growth (P-G) Matrix
Table 36.172 Small Molecules Continuous Manufacturing Market: Distribution by Key Geographical Regions, 2021, 2025 and 2035
Table 36.173 Small Molecules Continuous Manufacturing Market in North America: Historical Trends (Since 2021) and Forecasted Estimates (Till 2035) (USD Million): Conservative, Base and Optimistic Scenarios (USD Billion)
Table 36.174 Small Molecules Continuous Manufacturing Market in the US: Historical Trends (Since 2021) and Forecasted Estimates (Till 2035) (USD Million): Conservative, Base and Optimistic Scenarios (USD Billion)
Table 36.175 Small Molecules Continuous Manufacturing Market in Mexico: Historical Trends (Since 2021) and Forecasted Estimates (Till 2035) (USD Million): Conservative, Base and Optimistic Scenarios (USD Billion)
Table 36.176 Small Molecules Continuous Manufacturing Market in Europe: Historical Trends (Since 2021) and Forecasted Estimates (Till 2035) (USD Million): Conservative, Base and Optimistic Scenarios (USD Billion)
Table 36.177 Small Molecules Continuous Manufacturing Market in Germany: Historical Trends (Since 2021) and Forecasted Estimates (Till 2035) (USD Million): Conservative, Base and Optimistic Scenarios (USD Billion)
Table 36.178 Small Molecules Continuous Manufacturing Market in the UK: Historical Trends (Since 2021) and Forecasted Estimates (Till 2035) (USD Million): Conservative, Base and Optimistic Scenarios (USD Billion)
Table 36.179 Small Molecules Continuous Manufacturing Market in Italy: Historical Trends (Since 2021) and Forecasted Estimates (Till 2035) (USD Million): Conservative, Base and Optimistic Scenarios (USD Billion)
Table 36.180 Small Molecules Continuous Manufacturing Market in Switzerland: Historical Trends (Since 2021) and Forecasted Estimates (Till 2035) (USD Million): Conservative, Base and Optimistic Scenarios (USD Billion)
Table 36.181 Small Molecules Continuous Manufacturing Market in France: Historical Trends (Since 2021) and Forecasted Estimates (Till 2035) (USD Million): Conservative, Base and Optimistic Scenarios (USD Billion)
Table 36.182 Small Molecules Continuous Manufacturing Market in Belgium: Historical Trends (Since 2021) and Forecasted Estimates (Till 2035) (USD Million): Conservative, Base and Optimistic Scenarios (USD Billion)
Table 36.183 Small Molecules Continuous Manufacturing Market in Rest of Europe: Historical Trends (Since 2021) and Forecasted Estimates (Till 2035) (USD Million): Conservative, Base and Optimistic Scenarios (USD Billion)
Table 36.184 Small Molecules Continuous Manufacturing Market in Asia-Pacific: Historical Trends (Since 2021) and Forecasted Estimates (Till 2035) (USD Million): Conservative, Base and Optimistic Scenarios (USD Billion)
Table 36.185 Small Molecules Continuous Manufacturing Market in China: Historical Trends (Since 2021) and Forecasted Estimates (Till 2035) (USD Million): Conservative, Base and Optimistic Scenarios (USD Billion)
Table 36.186 Small Molecules Continuous Manufacturing Market in Singapore: Historical Trends (Since 2021) and Forecasted Estimates (Till 2035) (USD Million): Conservative, Base and Optimistic Scenarios (USD Billion)
Table 36.187 Small Molecules Continuous Manufacturing Market in Japan: Historical Trends (Since 2021) and Forecasted Estimates (Till 2035) (USD Million): Conservative, Base and Optimistic Scenarios (USD Billion)
Table 36.188 Small Molecules Continuous Manufacturing Market in India: Historical Trends (Since 2021) and Forecasted Estimates (Till 2035) (USD Million): Conservative, Base and Optimistic Scenarios (USD Billion)
Table 36.189 Small Molecules Continuous Manufacturing Market in South Korea: Historical Trends (Since 2021) and Forecasted Estimates (Till 2035) (USD Million): Conservative, Base and Optimistic Scenarios (USD Billion)

List of Companies

Please reach out to our team for the details